概述
基于多个公开的疾病知识库和文献挖掘数据，整合了超过2万个疾病专题。这些数据包括疾病概述、流行病学、机制研究、治疗方案、药物说明书、临床研究、临床指南、研究综述等信息。
数据结构及样例
{
"_id": "64bfa62763e3691230637d33",
"key_id": "5fbbab0021355b2ada1f7adb7687eca8",
"疾病名称": "Kidney Cancer",
"疾病中文名称": "肾癌",
"疾病别称": [
"Kidney Cancer",
"Renal Cancer",
"Renal Carcinoma",
"Kidney Neoplasm",
"Malignant Neoplasm of Kidney Except Pelvis",
"Malignant Neoplasm of Kidney",
"Malignant Tumour of Kidney",
"Renal Cell Carcinoma",
"Kidney Neoplasms",
"Cancer, Kidney",
"Cancer, Renal"
],
"疾病中文别称": [
"肾癌",
"肾肿瘤",
"恶性肾肿瘤（除盆腔外）",
"恶性肾肿瘤",
"肾细胞癌",
"癌症，肾脏"
],
"disease_categories_global": [
{
"整体英文分类": "Metabolic diseases",
"整体中文分类": "代谢性疾病"
},
{
"MedlinePlus英文概述": "Cancer diseases",
"MedlinePlus中文概述": "癌症"
}
],
"disease_categories_anatomical": [
{
"解剖学英文分类": "Nephrological diseases",
"解剖学中文分类": "肾脏疾病"
},
{
"MedlinePlus英文概述": "Endocrine diseases",
"MedlinePlus中文概述": "内分泌疾病"
}
],
"omim编码": "",
"mesh编码": "D007680",
"do_code": [
"DOID:263"
],
"icd11_code": [
"EFO_0002890",
"EFO_0003865"
],
"icd10编码": [],
"icd9编码": "189.0",
"snomed_ct编码": [],
"umls_code": [
"EFO_0002890",
"EFO_0003865"
],
"summary_omim": {
"omim英文概述": "",
"omimz中文概述": ""
},
"summary_gard": {
"GARD英文概述": "",
"GARD中文概述": ""
},
"summary_do": {
"Disease ontology英文概述": "A urinary system cancer that is located in the kidney.",
"Disease ontology中文概述": "一种位于肾脏的泌尿系统癌症。"
},
"summary_uniprot": {
"Uniprot英文概述": "",
"Uniprot中文概述": ""
},
"summary_malacards": {
"malacards英文概述": "Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma, nonpapillary and wilms tumor 1, and has symptoms including flank pain An important gene associated with Kidney Cancer is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are MicroRNAs in cardiomyocyte hypertrophy and miRNA role in immune response in sepsis. The drugs Bupivacaine and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include kidney and brain.",
"malacards中文概述": "肾癌，也称为肾癌，与肾细胞癌、非状瘤和肾母细胞瘤 1 有关，症状包括腰痛 与肾癌相关的一个重要基因是 HOTAIR（HOX 转录反义 RNA），其相关途径/超途径包括心肌细胞肥大的 MicroRNA 和 miRNA 在败血症免疫应答中的作用。药物布比卡因和尼古丁已在这种疾病的背景下被提及。附属组织包括肾脏和大脑。"
},
"summary_medlineplus": {
"MedlinePlus英文概述": "",
"MedlinePlus中文概述": ""
},
"genecards_pathways": [
{
"超级通路": "MicroRNAs in cardiomyocyte hypertrophy 74 Show member pathways Cardiac hypertrophic response 74",
"top_affiliating_genes": [
"MIR214",
"MIR21",
"MIR185"
]
},
{
"超级通路": "miRNA role in immune response in sepsis 74",
"top_affiliating_genes": [
"MIR21",
"MIR200C",
"MIR126"
]
},
{
"超级通路": "miRNAs involved in DNA damage response 74",
"top_affiliating_genes": [
"MIR27A",
"MIR210",
"MIR21",
"MIR17"
]
},
{
"超级通路": "Interactions between immune cells and microRNAs in tumor microenvironment 74",
"top_affiliating_genes": [
"MIR27A",
"MIR214",
"MIR210",
"MIR21",
"MIR200C"
]
},
{
"超级通路": "ncRNAs involved in STAT3 signaling in hepatocellular carcinoma 74",
"top_affiliating_genes": [
"MIR21",
"MIR200C"
]
}
],
"相关症状或临床表现": [],
"相关基因或增强子": [
{
"基因名称": "HOTAIR",
"描述": "HOX Transcript Antisense RNA",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "PVT1",
"描述": "Pvt1 Oncogene",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "GAS5",
"描述": "Growth Arrest Specific 5",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "KCNQ1OT1",
"描述": "KCNQ1 Opposite Strand/Antisense Transcript 1",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "HIF1A-AS2",
"描述": "HIF1A Antisense RNA 2",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MALAT1",
"描述": "Metastasis Associated Lung Adenocarcinoma Transcript 1",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MEG3",
"描述": "Maternally Expressed 3",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "HIF1A-AS1",
"描述": "HIF1A Antisense RNA 1",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "RNY3",
"描述": "RNA, Ro60-Associated Y3",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "EPB41L4A-DT",
"描述": "EPB41L4A Divergent Transcript",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "RNY1",
"描述": "RNA, Ro60-Associated Y1",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "H19",
"描述": "H19 Imprinted Maternally Expressed Transcript",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR21",
"描述": "MicroRNA 21",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR210",
"描述": "MicroRNA 210",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR17",
"描述": "MicroRNA 17",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR126",
"描述": "MicroRNA 126",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR200C",
"描述": "MicroRNA 200c",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR214",
"描述": "MicroRNA 214",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR27A",
"描述": "MicroRNA 27a",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR185",
"描述": "MicroRNA 185",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR141",
"描述": "MicroRNA 141",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR106B",
"描述": "MicroRNA 106b",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR150",
"描述": "MicroRNA 150",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR182",
"描述": "MicroRNA 182",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR29C",
"描述": "MicroRNA 29c",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR532",
"描述": "MicroRNA 532",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR424",
"描述": "MicroRNA 424",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR28",
"描述": "MicroRNA 28",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR15A",
"描述": "MicroRNA 15a",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR122",
"描述": "MicroRNA 122",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR29A",
"描述": "MicroRNA 29a",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR20A",
"描述": "MicroRNA 20a",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR106A",
"描述": "MicroRNA 106a",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR342",
"描述": "MicroRNA 342",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR378A",
"描述": "MicroRNA 378a",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR200B",
"描述": "MicroRNA 200b",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR191",
"描述": "MicroRNA 191",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR20B",
"描述": "MicroRNA 20b",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR489",
"描述": "MicroRNA 489",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR340",
"描述": "MicroRNA 340",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR7-2",
"描述": "MicroRNA 7-2",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIRLET7F2",
"描述": "MicroRNA Let-7f-2",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MTOR",
"描述": "Mechanistic Target Of Rapamycin Kinase",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Serine/threonine-protein kinase mTOR,2.7.11.1FK506-binding protein 12-rapamycin complex-associated protein 1,FKBP12-rapamycin complex-associated protein,Mammalian target of rapamycin,Mechanistic target of rapamycin,Rapamycin and FKBP12 target 1,Rapamycin target protein 1",
"功能": "Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals (PubMed:12087098, PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, PubMed:26018084). MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) (PubMed:15268862, PubMed:15467718, PubMed:18925875, PubMed:18497260, PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704). Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis (PubMed:12087098, PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, PubMed:26018084). This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E) (By similarity). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4 (PubMed:12150925, PubMed:12087098, PubMed:18925875). This also includes mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3: in the presence of nutrients, mediates phosphorylation of TFEB and TFE3, promoting their cytosolic retention and inactivation (PubMed:22576015, PubMed:22343943, PubMed:22692423). Upon starvation or lysosomal stress, inhibition of mTORC1 induces dephosphorylation and nuclear translocation of TFEB and TFE3, promoting their transcription factor activity (PubMed:22576015, PubMed:22343943, PubMed:22692423). Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex (PubMed:23429704, PubMed:23429703). Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor (PubMed:20516213). In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1 (By similarity). To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A (By similarity). mTORC1 also negatively regulates autophagy through phosphorylation of ULK1 (By similarity). Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1 (By similarity). Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP (PubMed:20537536). Also prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich conditions (PubMed:30704899). Prevents autophagy by mediating phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA (PubMed:23524951, PubMed:25438055). mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor (PubMed:21659604). Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules (PubMed:12231510). As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton (PubMed:15268862, PubMed:15467718). Plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1 (PubMed:15718470). mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B (PubMed:15268862). mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422' (PubMed:18925875). Regulates osteoclastogenesis by adjusting the expression of CEBPB isoforms (By similarity). Plays an important regulatory role in the circadian clock function; regulates period length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and liver clocks (By similarity). Phosphorylates SQSTM1, promoting interaction between SQSTM1 and KEAP1 and subsequent inactivation of the BCR(KEAP1) complex (By similarity)",
"pubmed_ids": [
"12087098",
"12150925",
"12150926",
"12231510",
"12718876",
"14651849",
"15268862",
"15467718",
"15545625",
"15718470",
"18497260",
"18762023",
"18925875",
"20516213",
"20537536",
"21576368",
"21659604",
"22343943",
"22576015",
"22692423",
"23429703",
"23429704",
"23524951",
"25438055",
"25799227",
"26018084",
"30704899"
]
}
]
},
{
"基因名称": "MET",
"描述": "MET Proto-Oncogene, Receptor Tyrosine Kinase",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Hepatocyte growth factor receptor,2.7.10.1HGF/SF receptor,Proto-oncogene c-Met,Scatter factor receptor,Tyrosine-protein kinase Met",
"功能": "Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity)\n(Microbial infection) Acts as a receptor for Listeria monocytogenes internalin InlB, mediating entry of the pathogen into cells",
"pubmed_ids": [
"11081636",
"17662939",
"19900460"
]
}
]
},
{
"基因名称": "VHL",
"描述": "Von Hippel-Lindau Tumor Suppressor",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "von Hippel-Lindau disease tumor suppressor,Protein G7,pVHL",
"功能": "Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2",
"pubmed_ids": [
"10944113",
"17981124",
"19584355"
]
}
]
},
{
"基因名称": "IL2",
"描述": "Interleukin 2",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Interleukin-2,T-cell growth factor",
"功能": "Cytokine produced by activated CD4-positive helper T-cells and to a lesser extend activated CD8-positive T-cells and natural killer (NK) cells that plays pivotal roles in the immune response and tolerance (PubMed:6438535). Binds to a receptor complex composed of either the high-affinity trimeric IL-2R (IL2RA/CD25, IL2RB/CD122 and IL2RC/CD132) or the low-affinity dimeric IL-2R (IL2RB and IL2RC) (PubMed:16293754, PubMed:16477002). Interaction with the receptor leads to oligomerization and conformation changes in the IL-2R subunits resulting in downstream signaling starting with phosphorylation of JAK1 and JAK3 (PubMed:7973659). In turn, JAK1 and JAK3 phosphorylate the receptor to form a docking site leading to the phosphorylation of several substrates including STAT5 (PubMed:8580378). This process leads to activation of several pathways including STAT, phosphoinositide-3-kinase/PI3K and mitogen-activated protein kinase/MAPK pathways (PubMed:25142963). Functions as a T-cell growth factor and can increase NK-cell cytolytic activity as well (PubMed:6608729). Promotes strong proliferation of activated B-cells and subsequently immunoglobulin production (PubMed:6438535). Plays a pivotal role in regulating the adaptive immune system by controlling the survival and proliferation of regulatory T-cells, which are required for the maintenance of immune tolerance. Moreover, participates in the differentiation and homeostasis of effector T-cell subsets, including Th1, Th2, Th17 as well as memory CD8-positive T-cells",
"pubmed_ids": [
"16293754",
"16477002",
"25142963",
"6438535",
"6608729",
"7973659",
"8580378"
]
}
]
},
{
"基因名称": "FH",
"描述": "Fumarate Hydratase",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Fumarate hydratase, mitochondrial,4.2.1.2",
"功能": "Catalyzes the reversible stereospecific interconversion of fumarate to L-malate (PubMed:30761759). Experiments in other species have demonstrated that specific isoforms of this protein act in defined pathways and favor one direction over the other (Probable)\nCatalyzes the hydration of fumarate to L-malate in the tricarboxylic acid (TCA) cycle to facilitate a transition step in the production of energy in the form of NADH\nCatalyzes the dehydration of L-malate to fumarate (By similarity). Fumarate metabolism in the cytosol plays a role during urea cycle and arginine metabolism; fumarate being a by-product of the urea cycle and amino-acid catabolism (By similarity). Also plays a role in DNA repair by promoting non-homologous end-joining (NHEJ) (PubMed:20231875, PubMed:26237645). In response to DNA damage and phosphorylation by PRKDC, translocates to the nucleus and accumulates at DNA double-strand breaks (DSBs): acts by catalyzing formation of fumarate, an inhibitor of KDM2B histone demethylase activity, resulting in enhanced dimethylation of histone H3 'Lys-36' (H3K36me2) (PubMed:26237645)",
"pubmed_ids": [
"30761759",
"20231875",
"26237645"
]
}
]
},
{
"基因名称": "FLCN",
"描述": "Folliculin",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Folliculin,BHD skin lesion fibrofolliculoma protein,Birt-Hogg-Dube syndrome protein",
"功能": "Multi-functional protein, involved in both the cellular response to amino acid availability and in the regulation of glycolysis (PubMed:17028174, PubMed:18663353, PubMed:21209915, PubMed:24081491, PubMed:24095279, PubMed:31704029, PubMed:31672913, PubMed:34381247). GTPase-activating protein that plays a key role in the cellular response to amino acid availability through regulation of the mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3 (PubMed:17028174, PubMed:18663353, PubMed:21209915, PubMed:24081491, PubMed:24095279, PubMed:31704029, PubMed:31672913). Regulates glycolysis by binding to lactate dehydrogenase LDHA, acting as an uncompetitive inhibitor (PubMed:34381247). Activates mTORC1 by acting as a GTPase-activating protein: specifically stimulates GTP hydrolysis by RRAGC/RagC or RRAGD/RagD, promoting the conversion to the GDP-bound state of RRAGC/RagC or RRAGD/RagD, and thereby activating the kinase activity of mTORC1 (PubMed:24095279, PubMed:31704029, PubMed:31672913). The GTPase-activating activity is inhibited during starvation and activated in presence of nutrients (PubMed:31672913). Acts as a key component for mTORC1-dependent control of the MiT/TFE factors TFEB and TFE3, while it is not involved in mTORC1-dependent phosphorylation of canonical RPS6KB1/S6K1 and EIF4EBP1/4E-BP1 (PubMed:21209915, PubMed:24081491, PubMed:31672913). In low-amino acid conditions, the lysosomal folliculin complex (LFC) is formed on the membrane of lysosomes, which inhibits the GTPase-activating activity of FLCN, inactivates mTORC1 and maximizes nuclear translocation of TFEB and TFE3 (PubMed:31672913). Upon amino acid restimulation, RRAGA/RagA (or RRAGB/RagB) nucleotide exchange promotes disassembly of the LFC complex and liberates the GTPase-activating activity of FLCN, leading to activation of mTORC1 and subsequent cytoplasmic retention of TFEB and TFE3 (PubMed:31672913). Indirectly acts as a positive regulator of Wnt signaling by promoting mTOR-dependent cytoplasmic retention of MiT/TFE factor TFE3 (PubMed:31272105). Required for the exit of hematopoietic stem cell from pluripotency by promoting mTOR-dependent cytoplasmic retention of TFE3, thereby increasing Wnt signaling (PubMed:30733432). Acts as an inhibitor of browning of adipose tissue by regulating mTOR-dependent cytoplasmic retention of TFE3 (By similarity). In response to flow stress, regulates STK11/LKB1 accumulation and mTORC1 activation through primary cilia: may act by recruiting STK11/LKB1 to primary cilia for activation of AMPK resided at basal bodies, causing mTORC1 down-regulation (PubMed:27072130). Together with FNIP1 and/or FNIP2, regulates autophagy: following phosphorylation by ULK1, interacts with GABARAP and promotes autophagy (PubMed:25126726). Required for starvation-induced perinuclear clustering of lysosomes by promoting association of RILP with its effector RAB34 (PubMed:27113757)",
"pubmed_ids": [
"17028174",
"18663353",
"21209915",
"24081491",
"24095279",
"25126726",
"27072130",
"27113757",
"30733432",
"31272105",
"31672913",
"31704029",
"34381247"
]
}
]
},
{
"基因名称": "VEGFA",
"描述": "Vascular Endothelial Growth Factor A",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Vascular endothelial growth factor A,Vascular permeability factor",
"功能": "Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437)",
"pubmed_ids": [
"11427521",
"16489009",
"17446437",
"25825981"
]
}
]
},
{
"基因名称": "CA9",
"描述": "Carbonic Anhydrase 9",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Carbonic anhydrase 9,4.2.1.1Carbonate dehydratase IX,Carbonic anhydrase IX,Membrane antigen MN,P54/58N,Renal cell carcinoma-associated antigen G250,pMW1",
"功能": "Catalyzes the interconversion between carbon dioxide and water and the dissociated ions of carbonic acid (i.e. bicarbonate and hydrogen ions)",
"pubmed_ids": [
"17314045",
"17705204",
"18703501",
"19186056",
"19206230",
"19805286"
]
}
]
},
{
"基因名称": "IFNA1",
"描述": "Interferon Alpha 1",
"类别": "Protein Coding",
"蛋白名称": []
},
{
"基因名称": "HIF1A",
"描述": "Hypoxia Inducible Factor 1 Subunit Alpha",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Hypoxia-inducible factor 1-alpha,ARNT-interacting protein,Basic-helix-loop-helix-PAS protein MOP1,Class E basic helix-loop-helix protein 78,Member of PAS protein 1,PAS domain-containing protein 8",
"功能": "Functions as a master transcriptional regulator of the adaptive response to hypoxia (PubMed:11292861, PubMed:11566883, PubMed:15465032, PubMed:16973622, PubMed:17610843, PubMed:18658046, PubMed:20624928, PubMed:22009797, PubMed:9887100, PubMed:30125331). Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia (PubMed:11292861, PubMed:11566883, PubMed:15465032, PubMed:16973622, PubMed:17610843, PubMed:20624928, PubMed:22009797, PubMed:9887100, PubMed:30125331). Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease (PubMed:22009797). Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300 (PubMed:9887100, PubMed:16543236). Activity is enhanced by interaction with NCOA1 and/or NCOA2 (PubMed:10594042). Interaction with redox regulatory protein APEX1 seems to activate CTAD and potentiates activation by NCOA1 and CREBBP (PubMed:10202154, PubMed:10594042). Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia (PubMed:19528298)\n(Microbial infection) Upon infection by human coronavirus SARS-CoV-2, is required for induction of glycolysis in monocytes and the consequent pro-inflammatory state (PubMed:32697943). In monocytes, induces expression of ACE2 and cytokines such as IL1B, TNF, IL6, and interferons (PubMed:32697943). Promotes human coronavirus SARS-CoV-2 replication and monocyte inflammatory response (PubMed:32697943)",
"pubmed_ids": [
"10202154",
"10594042",
"11292861",
"11566883",
"15465032",
"16543236",
"16973622",
"17610843",
"18658046",
"19528298",
"20624928",
"22009797",
"30125331",
"9887100",
"32697943"
]
}
]
},
{
"基因名称": "CD274",
"描述": "CD274 Molecule",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Programmed cell death 1 ligand 1,B7 homolog 1",
"功能": "Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077)\nThe PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity)",
"pubmed_ids": [
"10581077",
"11015443",
"28813410",
"28813417"
]
}
]
},
{
"基因名称": "SDHB",
"描述": "Succinate Dehydrogenase Complex Iron Sulfur Subunit B",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial,1.3.5.1Iron-sulfur subunit of complex II",
"功能": "Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q)",
"pubmed_ids": [
"26925370",
"27604842"
]
}
]
},
{
"基因名称": "FHIT",
"描述": "Fragile Histidine Triad Diadenosine Triphosphatase",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Bis(5'-adenosyl)-triphosphatase,3.6.1.29AP3A hydrolase,Adenosine 5'-monophosphoramidase FHIT,Adenylylsulfatase,Adenylylsulfate-ammonia adenylyltransferase,Diadenosine 5',5'''-P1,P3-triphosphate hydrolase,Dinucleosidetriphosphatase,Fragile histidine triad protein",
"功能": "Possesses dinucleoside triphosphate hydrolase activity (PubMed:12574506, PubMed:15182206, PubMed:8794732, PubMed:9323207, PubMed:9576908, PubMed:9543008). Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP (PubMed:12574506, PubMed:15182206, PubMed:8794732, PubMed:9323207, PubMed:9576908, PubMed:9543008). Can also hydrolyze P(1)-P(4)-bis(5'-adenosyl) tetraphosphate (Ap4A), but has extremely low activity with ATP (PubMed:8794732). Exhibits adenylylsulfatase activity, hydrolyzing adenosine 5'-phosphosulfate to yield AMP and sulfate (PubMed:18694747). Exhibits adenosine 5'-monophosphoramidase activity, hydrolyzing purine nucleotide phosphoramidates with a single phosphate group such as adenosine 5'monophosphoramidate (AMP-NH2) to yield AMP and NH2 (PubMed:18694747). Exhibits adenylylsulfate-ammonia adenylyltransferase, catalyzing the ammonolysis of adenosine 5'-phosphosulfate resulting in the formation of adenosine 5'-phosphoramidate (PubMed:26181368). Also catalyzes the ammonolysis of adenosine 5-phosphorofluoridate and diadenosine triphosphate (PubMed:26181368). Modulates transcriptional activation by CTNNB1 and thereby contributes to regulate the expression of genes essential for cell proliferation and survival, such as CCND1 and BIRC5 (PubMed:18077326). Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways (PubMed:16407838). Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a role in p53/TP53-mediated apoptosis (PubMed:15313915). Induction of apoptosis depends on the ability of FHIT to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related compounds, but does not require its catalytic activity, it may in part come from the mitochondrial form, which sensitizes the low-affinity Ca(2+) transporters, enhancing mitochondrial calcium uptake (PubMed:12574506, PubMed:19622739). Functions as tumor suppressor (By similarity)",
"pubmed_ids": [
"12574506",
"15313915",
"16407838",
"18077326",
"18694747",
"19622739",
"26181368",
"8794732",
"9323207",
"9543008"
]
}
]
},
{
"基因名称": "RASSF1",
"描述": "Ras Association Domain Family Member 1",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Ras association domain-containing protein 1,",
"功能": "Potential tumor suppressor. Required for death receptor-dependent apoptosis. Mediates activation of STK3/MST2 and STK4/MST1 during Fas-induced apoptosis by preventing their dephosphorylation. When associated with MOAP1, promotes BAX conformational change and translocation to mitochondrial membranes in response to TNF and TNFSF10 stimulation. Isoform A interacts with CDC20, an activator of the anaphase-promoting complex, APC, resulting in the inhibition of APC activity and mitotic progression. Inhibits proliferation by negatively regulating cell cycle progression at the level of G1/S-phase transition by regulating accumulation of cyclin D1 protein. Isoform C has been shown not to perform these roles, no function has been identified for this isoform. Isoform A disrupts interactions among MDM2, DAXX and USP7, thus contributing to the efficient activation of TP53 by promoting MDM2 self-ubiquitination in cell-cycle checkpoint control in response to DNA damage",
"pubmed_ids": [
"10888881",
"11333291",
"12024041",
"14743218",
"15109305",
"15949439",
"16510573",
"18566590",
"21199877"
]
}
]
},
{
"基因名称": "TSC2",
"描述": "TSC Complex Subunit 2",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Tuberin,Tuberous sclerosis 2 protein",
"功能": "In complex with TSC1, this tumor suppressor inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling (PubMed:12271141, PubMed:28215400). Acts as a GTPase-activating protein (GAP) for the small GTPase RHEB, a direct activator of the protein kinase activity of mTORC1 (PubMed:15340059). May also play a role in microtubule-mediated protein transport (By similarity). Also stimulates the intrinsic GTPase activity of the Ras-related proteins RAP1A and RAB5 (By similarity)",
"pubmed_ids": [
"12271141",
"15340059",
"28215400"
]
}
]
},
{
"基因名称": "WT1",
"描述": "WT1 Transcription Factor",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Wilms tumor protein,WT33",
"功能": "Transcription factor that plays an important role in cellular development and cell survival (PubMed:7862533). Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:7862533, PubMed:17716689, PubMed:25258363). Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors (PubMed:15520190). Isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing (PubMed:16934801). Isoform 1 has lower affinity for DNA, and can bind RNA (PubMed:19123921)",
"pubmed_ids": [
"15520190",
"16934801",
"17716689",
"19123921",
"19416806",
"25258363",
"7862533"
]
}
]
},
{
"基因名称": "PLIN2",
"描述": "Perilipin 2",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Perilipin-2,Adipophilin,Adipose differentiation-related protein",
"功能": "Structural component of lipid droplets, which is required for the formation and maintenance of lipid storage droplets",
"pubmed_ids": [
"34077757"
]
}
]
},
{
"基因名称": "PIK3CA",
"描述": "Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform,2.7.1.137,2.7.1.153Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha,Phosphoinositide 3-kinase alpha,Phosphoinositide-3-kinase catalytic alpha polypeptide,Serine/threonine protein kinase PIK3CA",
"功能": "Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides (PubMed:15135396, PubMed:23936502, PubMed:28676499). Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396, PubMed:28676499). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. In addition to its lipid kinase activity, it displays a serine-protein kinase activity that results in the autophosphorylation of the p85alpha regulatory subunit as well as phosphorylation of other proteins such as 4EBP1, H-Ras, the IL-3 beta c receptor and possibly others (PubMed:23936502, PubMed:28676499). Plays a role in the positive regulation of phagocytosis and pinocytosis (By similarity)",
"pubmed_ids": [
"15135396",
"21708979",
"23936502",
"26593112",
"28676499"
]
}
]
},
{
"基因名称": "LINC02577",
"描述": "Long Intergenic Non-Protein Coding RNA 2577",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "GSTP1",
"描述": "Glutathione S-Transferase Pi 1",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Glutathione S-transferase P,2.5.1.18GST class-pi,GSTP1-1",
"功能": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2) (PubMed:9084911). Participates in the formation of novel hepoxilin regioisomers (PubMed:21046276). Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration",
"pubmed_ids": [
"21046276",
"21668448",
"9084911"
]
}
]
},
{
"基因名称": "TP53",
"描述": "Tumor Protein P53",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Cellular tumor antigen p53,Antigen NY-CO-13,Phosphoprotein p53,Tumor suppressor p53",
"功能": "Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:9840937, PubMed:24652652). Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:9840937, PubMed:24652652). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492)",
"pubmed_ids": [
"11025664",
"12524540",
"12810724",
"15186775",
"15340061",
"17317671",
"17349958",
"19556538",
"20673990",
"20959462",
"22726440",
"24051492",
"24652652",
"9840937"
]
}
]
},
{
"基因名称": "EGFR",
"描述": "Epidermal Growth Factor Receptor",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Epidermal growth factor receptor,2.7.10.1Proto-oncogene c-ErbB-1,Receptor tyrosine-protein kinase erbB-1",
"功能": "Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704, PubMed:17909029). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity)\nIsoform 2 may act as an antagonist of EGF action\n(Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins",
"pubmed_ids": [
"10805725",
"11116146",
"11483589",
"11602604",
"12297049",
"12297050",
"12620237",
"12873986",
"15374980",
"15590694",
"15611079",
"17115032",
"17909029",
"19560417",
"20462955",
"20837704",
"21258366",
"27153536",
"2790960",
"7679104",
"8144591",
"9419975",
"21516087"
]
}
]
},
{
"基因名称": "MIR199A1",
"描述": "MicroRNA 199a-1",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "AQP1",
"描述": "Aquaporin 1 (Colton Blood Group)",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Aquaporin-1,Aquaporin-CHIP,Urine water channel,Water channel protein for red blood cells and kidney proximal tubule",
"功能": "Forms a water-specific channel that provides the plasma membranes of red cells and kidney proximal tubules with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient",
"pubmed_ids": [
"1373524"
]
}
]
},
{
"基因名称": "SETD2",
"描述": "SET Domain Containing 2, Histone Lysine Methyltransferase",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Histone-lysine N-methyltransferase SETD2,2.1.1.359HIF-1,Huntingtin yeast partner B,Huntingtin-interacting protein 1,Huntingtin-interacting protein B,Lysine N-methyltransferase 3A,Protein-lysine N-methyltransferase SETD2,SET domain-containing protein 2,p231HBP",
"功能": "Histone methyltransferase that specifically trimethylates 'Lys-36' of histone H3 (H3K36me3) using dimethylated 'Lys-36' (H3K36me2) as substrate (PubMed:16118227, PubMed:19141475, PubMed:21526191, PubMed:21792193, PubMed:23043551, PubMed:27474439). It is capable of trimethylating unmethylated H3K36 (H3K36me0) in vitro (PubMed:19332550). Represents the main enzyme generating H3K36me3, a specific tag for epigenetic transcriptional activation (By similarity). Plays a role in chromatin structure modulation during elongation by coordinating recruitment of the FACT complex and by interacting with hyperphosphorylated POLR2A (PubMed:23325844). Acts as a key regulator of DNA mismatch repair in G1 and early S phase by generating H3K36me3, a mark required to recruit MSH6 subunit of the MutS alpha complex: early recruitment of the MutS alpha complex to chromatin to be replicated allows a quick identification of mismatch DNA to initiate the mismatch repair reaction (PubMed:23622243). Required for DNA double-strand break repair in response to DNA damage: acts by mediating formation of H3K36me3, promoting recruitment of RAD51 and DNA repair via homologous recombination (HR) (PubMed:24843002). Acts as a tumor suppressor (PubMed:24509477). H3K36me3 also plays an essential role in the maintenance of a heterochromatic state, by recruiting DNA methyltransferase DNMT3A (PubMed:27317772). H3K36me3 is also enhanced in intron-containing genes, suggesting that SETD2 recruitment is enhanced by splicing and that splicing is coupled to recruitment of elongating RNA polymerase (PubMed:21792193). Required during angiogenesis (By similarity). Required for endoderm development by promoting embryonic stem cell differentiation toward endoderm: acts by mediating formation of H3K36me3 in distal promoter regions of FGFR3, leading to regulate transcription initiation of FGFR3 (By similarity). In addition to histones, also mediates methylation of other proteins, such as tubulins and STAT1 (PubMed:27518565, PubMed:28753426). Trimethylates 'Lys-40' of alpha-tubulins such as TUBA1B (alpha-TubK40me3); alpha-TubK40me3 is required for normal mitosis and cytokinesis and may be a specific tag in cytoskeletal remodeling (PubMed:27518565). Involved in interferon-alpha-induced antiviral defense by mediating both monomethylation of STAT1 at 'Lys-525' and catalyzing H3K36me3 on promoters of some interferon-stimulated genes (ISGs) to activate gene transcription (PubMed:28753426)\n(Microbial infection) Recruited to the promoters of adenovirus 12 E1A gene in case of infection, possibly leading to regulate its expression",
"pubmed_ids": [
"16118227",
"19141475",
"21526191",
"21792193",
"23043551",
"23325844",
"23622243",
"24509477",
"24843002",
"27317772",
"27474439",
"27518565",
"28753426",
"11461154"
]
}
]
},
{
"基因名称": "CDKN2A",
"描述": "Cyclin Dependent Kinase Inhibitor 2A",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Tumor suppressor ARF,Alternative reading frame,Cyclin-dependent kinase inhibitor 2A,p14ARF",
"功能": "Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. Isoform smARF may be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP",
"pubmed_ids": [
"11314011",
"11314038",
"12660818",
"14636574",
"15361825",
"15567177",
"15876874",
"15989956",
"16713577",
"18305112",
"22094112",
"9724636"
]
},
{
"蛋白名称": "Cyclin-dependent kinase inhibitor 2A,Cyclin-dependent kinase 4 inhibitor A,Multiple tumor suppressor 1,p16-INK4a",
"功能": "Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein",
"pubmed_ids": [
"16782892",
"7972006"
]
}
]
},
{
"基因名称": "DROSHA",
"描述": "Drosha Ribonuclease III",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Ribonuclease 3,3.1.26.3Protein Drosha,Ribonuclease III,p241",
"功能": "Ribonuclease III double-stranded (ds) RNA-specific endoribonuclease that is involved in the initial step of microRNA (miRNA) biogenesis. Component of the microprocessor complex that is required to process primary miRNA transcripts (pri-miRNAs) to release precursor miRNA (pre-miRNA) in the nucleus. Within the microprocessor complex, DROSHA cleaves the 3' and 5' strands of a stem-loop in pri-miRNAs (processing center 11 bp from the dsRNA-ssRNA junction) to release hairpin-shaped pre-miRNAs that are subsequently cut by the cytoplasmic DICER to generate mature miRNAs. Involved also in pre-rRNA processing. Cleaves double-strand RNA and does not cleave single-strand RNA. Involved in the formation of GW bodies",
"pubmed_ids": [
"10948199",
"14508493",
"15531877",
"15565168",
"15574589",
"15589161",
"16751099",
"16906129",
"17159994",
"26027739",
"26748718"
]
}
]
},
{
"基因名称": "KDR",
"描述": "Kinase Insert Domain Receptor",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Vascular endothelial growth factor receptor 2,2.7.10.1Fetal liver kinase 1,Kinase insert domain receptor,Protein-tyrosine kinase receptor flk-1",
"功能": "Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC",
"pubmed_ids": [
"10102632",
"10368301",
"10600473",
"11387210",
"12649282",
"1417831",
"15026417",
"15215251",
"15962004",
"16966330",
"17303569",
"18529047",
"19668192",
"19834490",
"20080685",
"20224550",
"20705758",
"21893193",
"25825981",
"7929439",
"9160888",
"9804796",
"9837777"
]
}
]
},
{
"基因名称": "EPAS1",
"描述": "Endothelial PAS Domain Protein 1",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Endothelial PAS domain-containing protein 1,Basic-helix-loop-helix-PAS protein MOP2,Class E basic helix-loop-helix protein 73,HIF-1-alpha-like factor,Hypoxia-inducible factor 2-alpha,Member of PAS protein 2,PAS domain-containing protein 2",
"功能": "Transcription factor involved in the induction of oxygen regulated genes. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation requires recruitment of transcriptional coactivators such as CREBBP and probably EP300. Interaction with redox regulatory protein APEX1 seems to activate CTAD (By similarity)",
"pubmed_ids": []
}
]
},
{
"基因名称": "EGF",
"描述": "Epidermal Growth Factor",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Pro-epidermal growth factor,",
"功能": "EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMed:10964941)",
"pubmed_ids": [
"10964941",
"17671655"
]
}
]
},
{
"基因名称": "TSC1",
"描述": "TSC Complex Subunit 1",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Hamartin,Tuberous sclerosis 1 protein",
"功能": "In complex with TSC2, inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling (PubMed:12271141, PubMed:28215400). Seems not to be required for TSC2 GAP activity towards RHEB (PubMed:15340059). Implicated as a tumor suppressor. Involved in microtubule-mediated protein transport, but this seems to be due to unregulated mTOR signaling (By similarity). Acts as a co-chaperone for HSP90AA1 facilitating HSP90AA1 chaperoning of protein clients such as kinases, TSC2 and glucocorticoid receptor NR3C1 (PubMed:29127155). Increases ATP binding to HSP90AA1 and inhibits HSP90AA1 ATPase activity (PubMed:29127155). Competes with the activating co-chaperone AHSA1 for binding to HSP90AA1, thereby providing a reciprocal regulatory mechanism for chaperoning of client proteins (PubMed:29127155). Recruits TSC2 to HSP90AA1 and stabilizes TSC2 by preventing the interaction between TSC2 and ubiquitin ligase HERC1 (PubMed:16464865, PubMed:29127155)",
"pubmed_ids": [
"12271141",
"15340059",
"16464865",
"28215400",
"29127155"
]
}
]
},
{
"基因名称": "ELOB",
"描述": "Elongin B",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Elongin-B,Elongin 18 kDa subunit,RNA polymerase II transcription factor SIII subunit B,SIII p18,Transcription elongation factor B polypeptide 2",
"功能": "SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A is transcriptionally active and its transcription activity is strongly enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex) (PubMed:7638163). In embryonic stem cells, the elongin BC complex is recruited by EPOP to Polycomb group (PcG) target genes in order generate genomic region that display both active and repressive chromatin properties, an important feature of pluripotent stem cells (By similarity)\nCore component of multiple cullin-RING-based ECS (ElonginB/C-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complexes, which mediate the ubiquitination of target proteins (PubMed:10205047, PubMed:12004076, PubMed:12050673, PubMed:15590694, PubMed:26138980, PubMed:29779948, PubMed:29775578). This includes the von Hippel-Lindau ubiquitination complex CBC(VHL) (PubMed:10205047, PubMed:12004076, PubMed:12050673, PubMed:15590694). By binding to BC-box motifs it seems to link target recruitment subunits, like VHL and members of the SOCS box family, to Cullin/RBX1 modules that activate E2 ubiquitination enzymes (PubMed:10205047, PubMed:12004076, PubMed:12050673, PubMed:15590694). A number of ECS complexes (containing either KLHDC2, KLHDC3, KLHDC10, APPBP2, FEM1A, FEM1B or FEM1C as substrate-recognition component) are part of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:26138980, PubMed:29779948, PubMed:29775578)",
"pubmed_ids": [
"7638163",
"10205047",
"12004076",
"12050673",
"15590694",
"26138980",
"29775578",
"29779948"
]
}
]
},
{
"基因名称": "CUL2",
"描述": "Cullin 2",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Cullin-2,",
"功能": "Core component of multiple cullin-RING-based ECS (ElonginB/C-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complexes, which mediate the ubiquitination of target proteins (PubMed:11384984, PubMed:26138980, PubMed:29779948, PubMed:29775578). CUL2 may serve as a rigid scaffold in the complex and may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme (PubMed:9122164, PubMed:10973499, PubMed:11384984, PubMed:12609982, PubMed:24076655). The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1 (PubMed:12609982, PubMed:24076655, PubMed:27565346). The functional specificity of the ECS complex depends on the substrate recognition component (PubMed:9122164, PubMed:10973499, PubMed:26138980, PubMed:29779948, PubMed:29775578). ECS(VHL) mediates the ubiquitination of hypoxia-inducible factor (HIF) (PubMed:9122164, PubMed:10973499). A number of ECS complexes (containing either KLHDC2, KLHDC3, KLHDC10, APPBP2, FEM1A, FEM1B or FEM1C as substrate-recognition component) are part of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:26138980, PubMed:29779948, PubMed:29775578). ECS complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins (PubMed:27565346)",
"pubmed_ids": [
"10973499",
"11384984",
"12609982",
"24076655",
"26138980",
"27565346",
"29775578",
"29779948",
"9122164"
]
}
]
},
{
"基因名称": "VHLL",
"描述": "VHL Like",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "von Hippel-Lindau-like protein,",
"功能": "Functions as a dominant-negative VHL to serve as a protector of HIFalpha",
"pubmed_ids": [
"14757845"
]
}
]
},
{
"基因名称": "EIF4E",
"描述": "Eukaryotic Translation Initiation Factor 4E",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Eukaryotic translation initiation factor 4E,eIF-4F 25 kDa subunit,mRNA cap-binding protein",
"功能": "Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures (PubMed:16271312, PubMed:22578813). In addition to its role in translation initiation, also acts as a regulator of translation and stability in the cytoplasm (PubMed:24335285). Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression: in the complex, EIF4E mediates the binding to the mRNA cap (By similarity). Component of a multiprotein complex that sequesters and represses translation of proneurogenic factors during neurogenesis (By similarity). In P-bodies, component of a complex that mediates the storage of translationally inactive mRNAs in the cytoplasm and prevents their degradation (PubMed:24335285). May play an important role in spermatogenesis through translational regulation of stage-specific mRNAs during germ cell development (By similarity)",
"pubmed_ids": [
"16271312",
"22578813",
"24335285"
]
}
]
},
{
"基因名称": "RBX1",
"描述": "Ring-Box 1",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "E3 ubiquitin-protein ligase RBX1,2.3.2.27,2.3.2.32E3 ubiquitin-protein transferase RBX1,Protein ZYP,RING finger protein 75,RING-box protein 1,Regulator of cullins 1",
"功能": "E3 ubiquitin ligase component of multiple cullin-RING-based E3 ubiquitin-protein ligase (CRLs) complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins, including proteins involved in cell cycle progression, signal transduction, transcription and transcription-coupled nucleotide excision repair (PubMed:10230407, PubMed:10579999, PubMed:15983046, PubMed:16678110, PubMed:19112177, PubMed:19679664, PubMed:23455478, PubMed:27565346, PubMed:29769719, PubMed:11961546, PubMed:22748924). CRLs complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins, ARIH1 mediating addition of the first ubiquitin on CRLs targets (PubMed:27565346). The functional specificity of the E3 ubiquitin-protein ligase complexes depends on the variable substrate recognition components. As a component of the CSA complex promotes the ubiquitination of ERCC6 resulting in proteasomal degradation. Recruits the E2 ubiquitin-conjugating enzyme CDC34 to the complex and brings it into close proximity to the substrate. Probably also stimulates CDC34 autoubiquitination. May be required for histone H3 and histone H4 ubiquitination in response to ultraviolet and for subsequent DNA repair. Promotes the neddylation of CUL1, CUL2, CUL4 and CUL4 via its interaction with UBE2M. Involved in the ubiquitination of KEAP1, ENC1 and KLHL41. In concert with ATF2 and CUL3, promotes degradation of KAT5 thereby attenuating its ability to acetylate and activate ATM",
"pubmed_ids": [
"10230407",
"10579999",
"11027288",
"11961546",
"15983046",
"16678110",
"16751180",
"18397884",
"19112177",
"19679664",
"22748924",
"23455478",
"27565346",
"29769719"
]
}
]
},
{
"基因名称": "IFNA2",
"描述": "Interferon Alpha 2",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Interferon alpha-2,Interferon alpha-A",
"功能": "Produced by macrophages, IFN-alpha have antiviral activities",
"pubmed_ids": [
"6159538"
]
}
]
},
{
"基因名称": "SGK1",
"描述": "Serum/Glucocorticoid Regulated Kinase 1",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Serine/threonine-protein kinase Sgk1,2.7.11.1Serum/glucocorticoid-regulated kinase 1",
"功能": "Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarization and memory consolidation. Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na(+)/dicarboxylate cotransporter: SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Stimulates sodium transport into epithelial cells by enhancing the stability and expression of SCNN1A/ENAC. This is achieved by phosphorylating the NEDD4L ubiquitin E3 ligase, promoting its interaction with 14-3-3 proteins, thereby preventing it from binding to SCNN1A/ENAC and targeting it for degradation. Regulates store-operated Ca(+2) entry (SOCE) by stimulating ORAI1 and STIM1. Regulates KCNJ1/ROMK1 directly via its phosphorylation or indirectly via increased interaction with SLC9A3R2/NHERF2. Phosphorylates MDM2 and activates MDM2-dependent ubiquitination of p53/TP53. Phosphorylates MAPT/TAU and mediates microtubule depolymerization and neurite formation in hippocampal neurons. Phosphorylates SLC2A4/GLUT4 and up-regulates its activity. Phosphorylates APBB1/FE65 and promotes its localization to the nucleus. Phosphorylates MAPK1/ERK2 and activates it by enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. Phosphorylates FBXW7 and plays an inhibitory role in the NOTCH1 signaling. Phosphorylates FOXO1 resulting in its relocalization from the nucleus to the cytoplasm. Phosphorylates FOXO3, promoting its exit from the nucleus and interference with FOXO3-dependent transcription. Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits their activity. Phosphorylates SLC9A3/NHE3 in response to dexamethasone, resulting in its activation and increased localization at the cell membrane. Phosphorylates CREB1. Necessary for vascular remodeling during angiogenesis. Sustained high levels and activity may contribute to conditions such as hypertension and diabetic nephropathy. Isoform 2 exhibited a greater effect on cell plasma membrane expression of SCNN1A/ENAC and Na(+) transport than isoform 1",
"pubmed_ids": [
"11154281",
"11410590",
"11696533",
"12397388",
"12590200",
"12634932",
"12650886",
"12761204",
"12911626",
"14623317",
"14706641",
"15040001",
"15044175",
"15234985",
"15319523",
"15496163",
"15733869",
"15737648",
"15845389",
"15888551",
"16036218",
"16443776",
"16982696",
"17382906",
"18005662",
"18304449",
"18753299",
"19447520",
"19756449",
"20511718",
"20730100",
"21865597"
]
}
]
},
{
"基因名称": "H2AC18",
"描述": "H2A Clustered Histone 18",
"类别": "Protein Coding",
"蛋白名称": []
},
{
"基因名称": "DLEC1",
"描述": "DLEC1 Cilia And Flagella Associated Protein",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Deleted in lung and esophageal cancer protein 1,Deleted in lung cancer protein 1",
"功能": "Essential for spermatogenesis and male fertility (By similarity). May play an important role in sperm head and tail formation (By similarity). May act as a tumor suppressor by inhibiting cell proliferation",
"pubmed_ids": [
"10213508"
]
}
]
},
{
"基因名称": "ICOSLG",
"描述": "Inducible T Cell Costimulator Ligand",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "ICOS ligand,B7 homolog 2,B7-like protein Gl50,B7-related protein 1",
"功能": "Ligand for the T-cell-specific cell surface receptor ICOS. Acts as a costimulatory signal for T-cell proliferation and cytokine secretion; induces also B-cell proliferation and differentiation into plasma cells. Could play an important role in mediating local tissue responses to inflammatory conditions, as well as in modulating the secondary immune response by co-stimulating memory T-cell function (By similarity)",
"pubmed_ids": []
}
]
},
{
"基因名称": "MIR145",
"描述": "MicroRNA 145",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "CD44",
"描述": "CD44 Molecule (Indian Blood Group)",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "CD44 antigen,CDw44,Epican,Extracellular matrix receptor III,GP90 lymphocyte homing/adhesion receptor,HUTCH-I,Heparan sulfate proteoglycan,Hermes antigen,Hyaluronate receptor,Phagocytic glycoprotein 1,Phagocytic glycoprotein I",
"功能": "Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment (PubMed:16541107, PubMed:19703720, PubMed:22726066). Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection (PubMed:7528188). Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases (PubMed:18757307, PubMed:23589287). Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signaling pathways promoting calcium mobilization and actin-mediated cytoskeleton reorganization essential for cell migration and adhesion (PubMed:15123640)",
"pubmed_ids": [
"15123640",
"16541107",
"18757307",
"19703720",
"22726066",
"23589287",
"7528188"
]
}
]
},
{
"基因名称": "ABCB1",
"描述": "ATP Binding Cassette Subfamily B Member 1",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "ATP-dependent translocase ABCB1,ATP-binding cassette sub-family B member 1,Multidrug resistance protein 1,P-glycoprotein 1,Phospholipid transporter ABCB1",
"功能": "Translocates drugs and phospholipids across the membrane (PubMed:8898203, PubMed:2897240, PubMed:9038218). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed:8898203). Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:2897240, PubMed:9038218)",
"pubmed_ids": [
"2897240",
"8898203",
"9038218"
]
}
]
},
{
"基因名称": "MIR193A",
"描述": "MicroRNA 193a",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR30A",
"描述": "MicroRNA 30a",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "RAF1",
"描述": "Raf-1 Proto-Oncogene, Serine/Threonine Kinase",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "RAF proto-oncogene serine/threonine-protein kinase,2.7.11.1Proto-oncogene c-RAF,Raf-1",
"功能": "Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation",
"pubmed_ids": [
"11427728",
"11719507",
"15385642",
"15618521",
"15849194",
"16892053",
"16924233",
"9360956"
]
}
]
},
{
"基因名称": "MIR204",
"描述": "MicroRNA 204",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "PTPRG",
"描述": "Protein Tyrosine Phosphatase Receptor Type G",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Receptor-type tyrosine-protein phosphatase gamma,3.1.3.48",
"功能": "Possesses tyrosine phosphatase activity",
"pubmed_ids": [
"19167335"
]
}
]
},
{
"基因名称": "EPCAM",
"描述": "Epithelial Cell Adhesion Molecule",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Epithelial cell adhesion molecule,Adenocarcinoma-associated antigen,Cell surface glycoprotein Trop-1,Epithelial cell surface antigen,Epithelial glycoprotein,Epithelial glycoprotein 314,KS 1/4 antigen,KSA,Major gastrointestinal tumor-associated protein GA733-2,Tumor-associated calcium signal transducer 1",
"功能": "May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E",
"pubmed_ids": [
"15195135",
"15922867",
"19785009",
"20064925"
]
}
]
},
{
"基因名称": "FGF2",
"描述": "Fibroblast Growth Factor 2",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Fibroblast growth factor 2,Basic fibroblast growth factor,Heparin-binding growth factor 2",
"功能": "Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:8663044). Also acts as an integrin ligand which is required for FGF2 signaling (PubMed:28302677). Binds to integrin ITGAV:ITGB3 (PubMed:28302677). Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration (PubMed:8663044, PubMed:28302677). Functions as a potent mitogen in vitro (PubMed:1721615, PubMed:3964259, PubMed:3732516). Can induce angiogenesis (PubMed:23469107, PubMed:28302677). Mediates phosphorylation of ERK1/2 and thereby promotes retinal lens fiber differentiation (PubMed:29501879)",
"pubmed_ids": [
"1721615",
"29501879",
"3732516",
"3964259"
]
}
]
},
{
"基因名称": "PRKAB1",
"描述": "Protein Kinase AMP-Activated Non-Catalytic Subunit Beta 1",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "5'-AMP-activated protein kinase subunit beta-1,",
"功能": "Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex assembles, via its C-terminus that bridges alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3)",
"pubmed_ids": []
}
]
},
{
"基因名称": "MIR142",
"描述": "MicroRNA 142",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "MIR144",
"描述": "MicroRNA 144",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "HGF",
"描述": "Hepatocyte Growth Factor",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Hepatocyte growth factor,Hepatopoietin-A,Scatter factor",
"功能": "Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization",
"pubmed_ids": [
"15167892",
"20624990"
]
}
]
},
{
"基因名称": "FOLH1",
"描述": "Folate Hydrolase 1",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "Glutamate carboxypeptidase 2,3.4.17.21Cell growth-inhibiting gene 27 protein,Folate hydrolase 1,Folylpoly-gamma-glutamate carboxypeptidase,Glutamate carboxypeptidase II,Membrane glutamate carboxypeptidase,N-acetylated-alpha-linked acidic dipeptidase I,Prostate-specific membrane antigen,Pteroylpoly-gamma-glutamate carboxypeptidase",
"功能": "Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Involved in prostate tumor progression\nAlso exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC",
"pubmed_ids": []
}
]
},
{
"基因名称": "MIR23B",
"描述": "MicroRNA 23b",
"类别": "RNA Gene",
"蛋白名称": []
},
{
"基因名称": "CCR6",
"描述": "C-C Motif Chemokine Receptor 6",
"类别": "Protein Coding",
"蛋白名称": [
{
"蛋白名称": "C-C chemokine receptor type 6,Chemokine receptor-like 3,DRY6,G-protein coupled receptor 29,GPR-CY4,LARC receptor",
"功能": "Receptor for the C-C type chemokine CCL20 (PubMed:9169459). Binds to CCL20 and subsequently transduces a signal by increasing the intracellular calcium ion levels (PubMed:20068036). Although CCL20 is its major ligand it can also act as a receptor for non-chemokine ligands such as beta-defensins (PubMed:25585877). Binds to defensin DEFB1 leading to increase in intracellular calcium ions and cAMP levels. Its binding to DEFB1 is essential for the function of DEFB1 in regulating sperm motility and bactericidal activity (PubMed:25122636). Binds to defensins DEFB4 and DEFB4A/B and mediates their chemotactic effects (PubMed:20068036). The ligand-receptor pair CCL20-CCR6 is responsible for the chemotaxis of dendritic cells (DC), effector/ memory T-cells and B-cells and plays an important role at skin and mucosal surfaces under homeostatic and inflammatory conditions, as well as in pathology, including cancer and various autoimmune diseases. CCR6-mediated signals are essential for immune responses to microbes in the intestinal mucosa and in the modulation of inflammatory responses initiated by tissue insult and trauma (PubMed:21376174). CCR6 is essential for the recruitment of both the pro-inflammatory IL17 producing helper T-cells (Th17) and the regulatory T-cells (Treg) to sites of inflammation. Required for the normal migration of Th17 cells in Peyers-patches and other related tissue sites of the intestine and plays a role in regulating effector T-cell balance and distribution in inflamed intestine. Plays an important role in the coordination of early thymocyte precursor migration events important for normal subsequent thymocyte precursor development, but is not required for the formation of normal thymic natural regulatory T-cells (nTregs). Required for optimal differentiation of DN2 and DN3 thymocyte precursors. Essential for B-cell localization in the subepithelial dome of Peyers-patches and for efficient B-cell isotype switching to IgA in the Peyers-patches. Essential for appropriate anatomical distribution of memory B-cells in the spleen and for the secondary recall response of memory B-cells (By similarity). Positively regulates sperm motility and chemotaxis via its binding to CCL20 (PubMed:23765988)",
"pubmed_ids": [
"20068036",
"23765988",
"25122636",
"9169459",
"21376174",
"25585877"
]
}
]
}
],
"pubmed治疗概述": "",
"pubmed治疗概述翻译": "",
"cancer_treatment": [
{
"生物标志物": "VHL",
"异常改变": "Oncogenic mutations (germline)",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Belzutifan"
],
"evidence": [
"34818478",
"10.1200/JCO.2021.39.15_suppl.4555"
],
"方案概述": "Not TGA approved. FDA approved 2021-08-13. MK-6482-004. N=61. Objective response rate (ORR) 49% (30/61) for clear cell renal cell carcinomas. Progression-free survival (PFS) rate at 52 week 98%."
},
{
"生物标志物": "VHL",
"异常改变": "Oncogenic mutations (germline)",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Belzutifan"
],
"evidence": [
"10.1200/JCO.2020.38.15_suppl.5003"
],
"方案概述": "."
},
{
"生物标志物": "ALK",
"异常改变": "Fusion",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Crizotinib"
],
"evidence": [
"29079636"
],
"方案概述": "."
},
{
"生物标志物": "ALK",
"异常改变": "Fusion",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Alectinib"
],
"evidence": [
"29079636"
],
"方案概述": "."
},
{
"生物标志物": "CDH6",
"异常改变": "Protein expression",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"DS-6000a (anti-CDH6 antibody-drug conjugate)"
],
"evidence": [
"10.1200/JCO.2022.40.16_suppl.3002"
],
"方案概述": "NCT04707248. Phase 1 first-in-human evaluation of DS-6000a. 6 of 20 responder were seen across dosing levels. CDH is overexpressed in renal cell carcinoma and ovarian carcinoma. Cut-off to be determined."
},
{
"生物标志物": "PBRM1",
"异常改变": "Loss-of-function mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Talazoparib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Talazoparib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Loss-of-function mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Olaparib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Olaparib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Loss-of-function mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Rucaparib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Rucaparib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Loss-of-function mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Berzosertib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Berzosertib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Loss-of-function mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Ceralasertib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Ceralasertib"
],
"evidence": [
"33888468"
],
"方案概述": "PARP and ATR inhibitors were shown to be synthetically lethal in PBRM1-deficient tumours in cell line and Xenograft models."
},
{
"生物标志物": "PBRM1",
"异常改变": "Truncating mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Nivolumab"
],
"evidence": [
"31486842"
],
"方案概述": "Exploratory analysis of CheckMate025 data. Odds ratio of response and clinical beneift to Nivolumab were higher (2.34 and 2.14 respectively) in patients with PBRM1 mutations. RCC with PBRM1 mutation was associated with increased progression-free survival (PFS) (5.6 v 2.9 months) and overall survival (OS) (27.9 vs 20.9 months) respectively."
},
{
"生物标志物": "PTEN",
"异常改变": "Loss of protein expression",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Everolimus"
],
"evidence": [
"29390043"
],
"方案概述": "Against Sunitinib HR 2.5 ."
},
{
"生物标志物": "FLCN",
"异常改变": "Loss-of-function mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Olaparib"
],
"evidence": [
"33069804"
],
"方案概述": "Preclinical study. FLCN protein deficiency is associated with olaparib sensitivivty in cell line and xenograft models."
},
{
"生物标志物": "FLCN",
"异常改变": "Loss-of-function mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Sirolimus"
],
"evidence": [
"26418749"
],
"方案概述": "Preclinical study. MTOR inhibitor, sirolimus, showed suppression of the tumour growth in Flcn-deficient allograft xenograft models."
},
{
"生物标志物": "TSC1",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Everolimus"
],
"evidence": [
"26831717"
],
"方案概述": "Drug is PBS listed but not biomarker selected ."
},
{
"生物标志物": "TSC1",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Everolimus"
],
"evidence": [
"29390043"
],
"方案概述": "No survival benefit vs Sunitinib ."
},
{
"生物标志物": "TSC2",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Everolimus"
],
"evidence": [
"26831717"
],
"方案概述": "Drug is PBS listed, but not biomarker selected ."
},
{
"生物标志物": "TSC2",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Everolimus"
],
"evidence": [
"29390043"
],
"方案概述": "No survival benefit vs Sunitinib ."
},
{
"生物标志物": "VHL",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Belzutifan"
],
"evidence": [
"33888901"
],
"方案概述": "Phase 1. NCT02974738. The dose expansion cohort of this single-arm study with Belzutifan showed an objective response rate (ORR) of 25% (14/55). Disease control rate (DCR) was 80% (44/55). Note VHL mutational status was not reported in this study, although VHL loss is common in RCC."
},
{
"生物标志物": "MTOR",
"异常改变": "L1460P",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Temsirolimus"
],
"evidence": [
"26831717"
],
"方案概述": "OncoKB Level of Evidence (LOE) 3; Retrospective association only ."
},
{
"生物标志物": "MTOR",
"异常改变": "L2209V",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Temsirolimus"
],
"evidence": [
"26831717"
],
"方案概述": "OncoKB Level of Evidence (LOE) 3; Retrospective association only ."
},
{
"生物标志物": "MTOR",
"异常改变": "L2427Q",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Temsirolimus"
],
"evidence": [
"26831717"
],
"方案概述": "OncoKB Level of Evidence (LOE) 3; Retrospective association only ."
},
{
"生物标志物": "MTOR",
"异常改变": "Oncogenic mutations",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Everolimus"
],
"evidence": [
"26831717"
],
"方案概述": "Drug is PBS listed, but not biomarker selected ."
},
{
"生物标志物": "MTOR",
"异常改变": "Q2223K",
"癌症类型": "Renal cell carcinoma",
"therapy": [
"Everolimus"
],
"evidence": [
"26831717"
],
"方案概述": "OncoKB Level of Evidence (LOE) 3; Retrospective association only ."
}
],
"相关药品": [
{
"药物名称": "Recombinant Human Interleukin-2 for Injection",
"中文药物名称": "注射用重组人白介素-2",
"类别": [
"免疫系统用药",
"抗肿瘤药"
],
"适应症": "1. 用于肾细胞癌、黑色素瘤恶性肿瘤治疗，用于癌性胸腹积液的控制。"
},
{
"药物名称": "Recombinant Human Interferon α2b for Injection",
"中文药物名称": "注射用重组人干扰素α2b",
"类别": [
"抗微生物药",
"抗肿瘤药"
],
"适应症": "1.用于治疗某些病毒性疾病，如急慢性病毒性肝炎、带状疱疹、尖锐湿疣。2.用于治疗某些肿瘤，如毛细胞性白血病、慢性髓细胞性白血病、多发性骨髓瘤、非何杰金氏淋巴瘤、恶性黑色素瘤、肾细胞癌、喉乳头状瘤、卡波氏肉瘤、卵巢癌、基底细胞癌、表面膀胱癌等。"
},
{
"药物名称": "Recombinant Human Interleukin-2(125Ala) Injection",
"中文药物名称": "重组人白细胞介素-2(125Ala)注射液",
"类别": [
"抗肿瘤药",
"生物制品"
],
"适应症": "1、用于肾细胞癌、黑色素瘤、乳腺癌、膀胱癌、肝癌、直肠癌、淋巴癌、肺癌等恶性肿瘤的治疗，用于癌性胸腹水的控制，也可以用于淋巴因子激活的杀伤细胞的培养。2、用于手术、放疗及化疗后的肿瘤患者的治疗，可增强机体免疫功能。3、用于先天或后天免疫缺陷症的治疗，提高病人细胞免疫功能和抗感染能力。4、各种自身免疫病的治疗，如类风湿性关节炎、系统性红斑狼疮、干燥综合症等。5、对某些病毒性、杆菌性疾病、胞内寄生菌感染性疾病，如乙型肝炎、麻风病、肺结核、白色念珠菌感染等具有一定的治疗作用。"
},
{
"药物名称": "Recombinant Human Interferon α2b for Injection(P.putida)",
"中文药物名称": "注射用重组人干扰素α2b(假单胞菌)",
"类别": [
"抗微生物药",
"抗肿瘤药"
],
"适应症": "1.用于治疗某些病毒性疾病，如急慢性病毒性肝炎、带状疱疹、尖锐湿疣。2.用于治疗某些肿瘤，如毛细胞性白血病、慢性髓细胞性白血病、多发性骨髓瘤、非何杰金氏淋巴瘤、恶性黑色素瘤、肾细胞癌、喉乳头状瘤、卡波氏肉瘤、卵巢癌、基底细胞癌、表面膀胱癌等。"
},
{
"药物名称": "Recombinant Human Interleukin-2 for injection",
"中文药物名称": "注射用重组人白细胞介素-2",
"类别": [
"免疫系统用药",
"抗肿瘤药"
],
"适应症": "1．用于肾细胞癌、黑色素瘤、乳腺癌、膀胱癌、肝癌、直肠癌、淋巴癌、肺癌等恶性肿瘤的治疗，用于癌性胸腹水的控制，也可以用于淋巴因子激活的杀伤细胞的培养；2．用于手术，放疗及化疗后的肿瘤患者的治疗，可增强机体免疫功能；3．用于先天或后天免疫缺陷症的治疗，提高病人细胞免疫功能和抗感染能力；4．各种自身免疫疾病的治疗，如类风湿性关节炎、系统性红斑狼疮、干燥综合症等；5．对某些病毒性、杆菌性疾病、胞内寄生菌感染性疾病，如乙型肝炎、麻风病、肺结核、白色念珠菌感染等具有一定的治疗作用。"
},
{
"药物名称": "Recombinant Human Interferon α2b Injection",
"中文药物名称": "重组人干扰素α2b注射液",
"类别": [
"抗微生物药",
"抗肿瘤药"
],
"适应症": "1.本品适合治疗某些病毒性疾病，如急慢性病毒性肝炎、带状疱疹、尖锐湿疣。2.用于治疗某些肿瘤，如毛细胞性白血病、慢性髓细胞性白血病、多发性骨髓瘤、非何杰金氏淋巴瘤、恶性黑色素瘤、肾细胞癌、喉乳头状瘤、卡波氏肉瘤、卵巢癌、基底细胞癌、表面膀胱癌等。"
},
{
"药物名称": "Everolimus Tablets",
"中文药物名称": "依维莫司片",
"类别": [
"抗肿瘤药"
],
"适应症": "依维莫司适用于治疗以下患者：·既往接受舒尼替尼或索拉非尼治疗失败的晚期肾细胞癌成人患者。·不可切除的、局部晚期或转移性的、分化良好的(中度分化或高度分化)进展期胰腺神经内分泌瘤成人患者。·无法手术切除的、局部晚期或转移性的、分化良好的、进展期非功能性胃肠道或肺源神经内分泌肿瘤(NET)成人患者。·需要治疗干预但不适于手术切除的结节性硬化症(TSC)相关的室管膜下巨细胞星形细胞瘤(SEGA)成人和儿童患者。本品的有效性主要通过可持续的客观缓解(即SEGA肿瘤体积的缩小)来证明。尚未证明结节性硬化症相关的室管膜下巨细胞星形细胞瘤的患者能否获得疾病相关症状改善和总生存期延长。·用于治疗不需立即手术治疗的结节性硬化症相关的肾血管平滑肌脂肪瘤(TSC-AML)成人患者。"
},
{
"药物名称": "Recombinant Human Interleukin-2(125Ser)for Injection",
"中文药物名称": "注射用重组人白细胞介素-2(125Ser)",
"类别": [
"免疫系统用药",
"抗肿瘤药"
],
"适应症": "1.用于肾细胞癌、黑色素瘤、乳腺癌、膀胱癌、肝癌、直肠癌、淋巴癌、肺癌等恶性肿瘤的治疗，用于癌性胸腹水的控制，也可以用于淋巴因子激活的杀伤细胞的培养。2.用于手术、放疗及化疗后的肿瘤患者的治疗，可增强机体免疫功能。3.用于先天或后天免疫缺陷症的治疗，提高病人细胞免疫功能和抗感染能力。4.各种自身免疫病的治疗，如类风湿性关节炎、系统性红斑狼疮、干燥综合症等。5.对某些病毒性、杆菌性疾病、胞内寄生菌感染性疾病，如乙型肝炎、麻风病、肺结核、白色念珠菌感染等具有一定的治疗作用。"
},
{
"药物名称": "Recombinant Human Interleukin-2(Ⅰ) for Injection",
"中文药物名称": "注射用重组人白介素-2(Ⅰ)",
"类别": [
"免疫系统用药",
"抗肿瘤药"
],
"适应症": "1.用于肾细胞癌、黑色素瘤、乳腺癌、膀胱癌、肝癌、直肠癌、淋巴癌、肺癌等恶性肿癌的治疗。用于癌性胸腹水的控制。也可以用于淋巴因子激活的杀伤细胞的培养。\n2.用于手术、化疗及放疗后的癌症患者的治疗，可加强机体免疫功能。\n3.用于先天或后天免疫缺陷症的治疗，提高病人细胞免疫功能和抗感染能力。\n4.各种自身免疫病的治疗，如类风湿性关节炎、系统性红斑狼疮、干燥综合征等。\n5.对某些病毒性、杆菌性、胞内寄生菌感染性疾病，如乙型肝炎、麻风病、肺结核、白色念珠菌感染等具有一定的治疗作用。"
},
{
"药物名称": "Sorafenib Tosylate Tablets",
"中文药物名称": "甲苯磺酸索拉非尼片",
"类别": [
"抗肿瘤药"
],
"适应症": "1、治疗不能手术的晚期肾细胞癌。2、治疗无法手术或远处转移的肝细胞癌。目前缺乏在晚期肝细胞癌患者中索拉非尼与介入治疗如肝动脉栓塞化疗(TACE)比较的随机对照临床研究数据，因此尚不能明确本品相对介入治疗的优劣，也不能明确对既往接受过介入治疗后患者使用索拉非尼是否有益(见【临床试验】项)。建议医生根据患者具体情况综合考虑，选择适宜治疗手段。3、治疗局部复发或转移的进展性的放射性碘难治性分化型甲状腺癌。"
},
{
"药物名称": "Recombinant Human Interleukin-2(125Ala) for Injection",
"中文药物名称": "注射用重组人白介素-2（125Ala）",
"类别": [
"生物制品"
],
"适应症": "1、用于肾细胞癌、黑色素瘤、乳腺癌、膀胱癌、肝癌、直肠癌、淋巴癌、肺癌等恶性肿瘤的治疗，用于癌性胸腹水的控制，也可以用于淋巴因子激活的杀伤细胞的培养。2、用于手术、放疗及化疗后的肿瘤患者的治疗，可增强机体免疫功能。3、用于先天或后天免疫缺陷症的治疗，提高病人细胞免疫功能和抗感染能力。4、各种自身免疫病的治疗，如类风湿性关节炎、系统性红斑狼疮、干燥综合症等。5、对某些病毒性、杆菌性疾病、胞内寄生菌感染性疾病，如乙型肝炎、麻风病、肺结核、白色念珠菌感染等具有一定的治疗作用。"
},
{
"药物名称": "Interferon alfa-2b Injection",
"中文药物名称": "重组人干扰素α-2b注射液",
"类别": [
"抗微生物药",
"抗肿瘤药"
],
"适应症": "本品可用于以下适应症：全身给药1.慢性乙型肝炎 用于治疗成人和儿童(≥1岁)代偿性肝病患者，患者的血清HBsAg阳性至少达6个月，同时存在乙型肝炎(以下简称乙肝)病毒(HBV)复制(血清HBeAg阳性)和血清丙氨酸氨基转移酶(ALT)升高。 在开始用本品治疗前，建议先进行肝组织活检，以便确诊慢性肝炎及肝损伤的程度。 在本品治疗慢性乙肝的大量临床研究中采用了下列标准，慢性乙肝患者使用本品治疗前可作为参考指标：\t\t\t\t\t\t*无肝性脑病、静脉曲张出血、腹水史及其他临床失代偿的表现。\t\t\t*胆红素 正常\t\t\t*白蛋白 稳定在正常范围内\t\t\t*凝血酶原时间 成人延长＜3秒钟\t\t\t 儿童延长≤2秒钟\t\t\t*白细胞 ≥4×109/l\t\t\t*血小板 成人≥100×109/l\t\t\t 儿童≥150×109/l\t\t\t2.慢性丙型肝炎 本品单独给药或与利巴韦林合用，对于肝酶升高而无肝脏失代偿的慢性丙型肝炎(以下简称丙肝)成人患者，可缓解疾病的活动程度。在这些患者身上进行的许多研究表明，本品可使血清ALT转为正常，血清HCV-RNA被清除，肝组织学病变改善。 使用本品12～18个月的患者的临床经验表明，较长疗程的患者比用药6个月后停药的患者的持续应答率更高。 在本品治疗的慢性丙肝的大量临床研究中采用了下列标准，慢性丙肝患者采用本品治疗前可考虑作为参考：\t\t\t\t\t\t*胆红素 ≤2mg/dl\t\t\t*白蛋白 稳定在正常范围内\t\t\t*凝血酶原时间 延长＜3秒钟\t\t\t*白细胞 ≥3×109/l\t\t\t*血小板 ≥70×109/l\t\t\t*血清肌酐 正常或接近正常\t\t\t3.慢性丁型肝炎 治疗慢性丁型肝炎(以下简称丁肝)患者。4.喉乳头状瘤 治疗喉乳头状瘤的儿童或成人患者。5.多毛细胞白血病 治疗多毛细胞白血病患者。6.慢性髓细胞性白血病(CML) 本品单独给药或与阿糖胞苷(Ara-C)合用，治疗慢性髓细胞性白血病患者。7.与慢性髓细胞性白血病(CML)有关的血小板增多症 血小板增多症常与CML有关。本品在治疗与CML有关的血小板增多症方面已有疗效。8.多发性骨髓瘤 对于采用诱导疗法取得实质性缓解的患者和复发患者，本品可作为维持疗法。9.非何杰金淋巴瘤 结合适当的化疗方案，如环磷酰胺-羟基柔红霉素-长春新碱-泼尼松(CHOP)化疗方案，本品可治疗高肿瘤负荷(Ⅲ或Ⅳ期)滤泡性淋巴瘤。10.艾滋病有关的卡波氏肉瘤 治疗与艾滋病相关的卡波氏肉瘤患者，患者无机会性感染病史，同时CD4＞250×106/l。11.肾细胞癌 治疗晚期肾癌患者。12.转移性类癌瘤(胰腺内分泌肿瘤) 治疗转移性类癌瘤患者。13.恶性黑色素瘤 作为手术后无病变但处于高度复发危险的成人黑色素瘤患者的辅助治疗。"
},
{
"药物名称": "Sunitinib Malate Capsules",
"中文药物名称": "苹果酸舒尼替尼胶囊",
"类别": [
"抗肿瘤药"
],
"适应症": "1)不能手术的晚期肾细胞癌(RCC)2)甲磺酸伊马替尼治疗失败或不能耐受的胃肠间质瘤(GIST)3)不可切除的，转移性高分化进展期胰腺神经内分泌瘤(pNET)成年患者。本品作为一线治疗的经验有限。"
},
{
"药物名称": "Axitinib Tablets",
"中文药物名称": "阿昔替尼片",
"类别": [
"抗肿瘤药"
],
"适应症": "阿昔替尼用于既往接受过一种酪氨酸激酶抑制剂或细胞因子治疗失败的进展期肾细胞癌(RCC)的成人患者。"
},
{
"药物名称": "Pazopanib Tablets",
"中文药物名称": "培唑帕尼片",
"类别": [
"抗肿瘤药"
],
"适应症": "本品适用于晚期肾细胞癌患者的一线治疗和曾接受细胞因子治疗的晚期肾细胞癌患者的治疗。"
},
{
"药物名称": "",
"中文药物名称": "注射用重组人白介素-2(125Ala)",
"类别": [
"抗肿瘤药"
],
"适应症": "1.本品可用于肾细胞癌、黑色素瘤、乳腺癌、膀胱癌、肝癌、直肠癌、淋巴癌、肺癌等恶性肿瘤的治疗，用于癌性胸腹水的控制，也可以用于淋巴因子激活的杀伤细胞的培养。2.用于手术前后及放疗、化疗后的肿瘤患者的治疗，可增强机体免疫功能。3.用于先天或后天免疫缺陷症的治疗。提高病人细胞免疫功能和抗感染能力。4.各种自身免疫病的治疗，如类风湿性关节炎、系统性红斑狼疮、干燥综合症等。5.对某些病毒性、杆菌性疾病，胞内寄生菌感染性疾病，如乙型肝炎、麻风病、肺结核、白色念球菌感染等具有一定的治疗作用。"
}
],
"鉴别诊断": [
{
"鉴别诊断": [
"Depression",
"Thyroid disease",
"Chronic liver or renal disease",
"Chronic infection, e.g., tuberculosis, endocarditis",
"Rheumatologic disease",
"Malabsorption, e.g., Whipple's disease"
],
"勿漏鉴别": [],
"关联待诊": [
"Fever of unknown origin",
"Involuntary weight loss",
"Paraneoplastic syndromes",
"Fatigue and weight loss",
"Pleural effusion and fever"
]
},
{
"鉴别诊断": [
"Transitional cell carcinoma (urethra, bladder, ureter, or renal pelvis)",
"Renal cyst",
"Adrenal tumor",
"Renal abscess",
"Renal oncocytoma",
"Renal angiomyolipoma",
"Metastases, eg, lung, breast, stomach, contralateral kidney",
"Lymphoma",
"Urinary calculi",
"Renal infarction"
],
"勿漏鉴别": [],
"关联待诊": [
"Hematuria",
"Renal cysts",
"Fatigue and fever",
"Abdominal pain and hematuria",
"Fatigue and fever"
]
}
],
"summary_table_incidence": [
{
"表名": "Kidney Cancer (Renal Cancer); Renal Pelvis Cancer",
"summary_content_incidence": [
{
"序号": "1",
"年龄分组": "all ages",
"发病数": "7,379",
"发病率（per100,000）": "10.4",
"国家/地区": "<sup>1</sup> Canada",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "2",
"年龄分组": "all ages",
"发病数": "79,000",
"发病率（per100,000）": "23.3",
"国家地区": "<sup>2</sup> U.S.",
"人群基数": {
"人群基数": "339,665,118",
"是否有星号": "yes"
}
},
{
"序号": "3",
"年龄分组": "all ages",
"发病数": "11,971",
"发病率（per100,000）": "4.5",
"国家地区": "<sup>3</sup> Brazil",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "4",
"年龄分组": "all ages",
"发病数": "5,925",
"发病率（per100,000）": "4.4",
"国家地区": "<sup>4</sup> Mexico",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "5",
"年龄分组": "all ages",
"发病数": "934",
"发病率（per100,000）": "15.7",
"国家地区": "<sup>5</sup> Denmark",
"人群基数": {
"人群基数": "5,946,984",
"是否有星号": "yes"
}
},
{
"序号": "6",
"年龄分组": "all ages",
"发病数": "1,056",
"发病率（per100,000）": "18.8",
"国家地区": "<sup>6</sup> Finland",
"人群基数": {
"人群基数": "5,614,571",
"是否有星号": "yes"
}
},
{
"序号": "7",
"年龄分组": "all ages",
"发病数": "14,705",
"发病率（per100,000）": "11.2",
"国家地区": "<sup>7</sup> France",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "8",
"年龄分组": "all ages",
"发病数": "17,336",
"发病率（per100,000）": "8.9",
"国家地区": "<sup>8</sup> Germany",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "9",
"年龄分组": "all ages",
"发病数": "12,306",
"发病率（per100,000）": "8.9",
"国家地区": "<sup>9</sup> Italy",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "10",
"年龄分组": "all ages",
"发病数": "957",
"发病率（per100,000）": "17.1",
"国家地区": "<sup>10</sup> Norway",
"人群基数": {
"人群基数": "5,597,924",
"是否有星号": "yes"
}
},
{
"序号": "11",
"年龄分组": "all ages",
"发病数": "25,087",
"发病率（per100,000）": "10.3",
"国家地区": "<sup>11</sup> Russia",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "12",
"年龄分组": "all ages",
"发病数": "8,554",
"发病率（per100,000）": "9.0",
"国家地区": "<sup>12</sup> Spain",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "13",
"年龄分组": "all ages",
"发病数": "1,468",
"发病率（per100,000）": "7.7",
"国家地区": "<sup>13</sup> Sweden",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "14",
"年龄分组": "all ages",
"发病数": "14,110",
"发病率（per100,000）": "10.3",
"国家地区": "<sup>14</sup> UK",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "15",
"年龄分组": "all ages",
"发病数": "73,587",
"发病率（per100,000）": "3.3",
"国家地区": "<sup>15</sup> China",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "16",
"年龄分组": "all ages",
"发病数": "16,861",
"发病率（per100,000）": "1.3",
"国家地区": "<sup>16</sup> India",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "17",
"年龄分组": "all ages",
"发病数": "25,145",
"发病率（per100,000）": "7.6",
"国家地区": "<sup>17</sup> Japan",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "18",
"年龄分组": "all ages",
"发病数": "2022 age-standardized incidence rate of kidney cancer; no calculations made",
"发病率（per100,000）": "7.4",
"国家地区": "<sup>18</sup> Korea (South)",
"人群基数": {
"人群基数": "2022 age-standardized incidence rate of kidney cancer; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "19",
"年龄分组": "all ages",
"发病数": "5,125",
"发病率（per100,000）": "5.3",
"国家地区": "<sup>19</sup> Turkey",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "20",
"年龄分组": "all ages",
"发病数": "475",
"发病率（per100,000）": "1.3",
"国家地区": "<sup>20</sup> Kenya",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "21",
"年龄分组": "all ages",
"发病数": "2,608",
"发病率（per100,000）": "2.2",
"国家地区": "<sup>21</sup> Nigeria",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "22",
"年龄分组": "all ages",
"发病数": "1,333",
"发病率（per100,000）": "2.6",
"国家地区": "<sup>22</sup> South Africa",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "23",
"年龄分组": "all ages",
"发病数": "4,573",
"发病率（per100,000）": "10.5",
"国家地区": "<sup>23</sup> Australia",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "24",
"年龄分组": "all ages",
"发病数": "9,509",
"发病率（per100,000）": "1.2",
"国家地区": "<sup>24</sup> Africa",
"人群基数": {
"人群基数": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "25",
"年龄分组": "unspecified",
"发病数": "Africa (Central Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "2.7",
"国家地区": "<sup>25</sup> Africa (Central Sub-Saharan)",
"人群基数": {
"人群基数": "Africa (Central Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "26",
"年龄分组": "unspecified",
"发病数": "Africa (Eastern Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "2.5",
"国家地区": "<sup>26</sup> Africa (Eastern Sub-Saharan)",
"人群基数": {
"人群基数": "Africa (Eastern Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "27",
"年龄分组": "unspecified",
"发病数": "Africa (Southern Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "3.3",
"国家地区": "<sup>27</sup> Africa (Southern Sub-Saharan)",
"人群基数": {
"人群基数": "Africa (Southern Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "28",
"年龄分组": "unspecified",
"发病数": "Africa (Western Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "2.9",
"国家地区": "<sup>28</sup> Africa (Western Sub-Saharan)",
"人群基数": {
"人群基数": "Africa (Western Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "29",
"年龄分组": "all ages",
"发病数": "99,362",
"发病率（per100,000）": "7.3",
"国家地区": "<sup>29</sup> Americas",
"人群基数": {
"人群基数": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "30",
"年龄分组": "unspecified",
"发病数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "6.3",
"国家地区": "<sup>30</sup> Asia (Central)",
"人群基数": {
"人群基数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "31",
"年龄分组": "unspecified",
"发病数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "2.8",
"国家地区": "<sup>31</sup> Asia (East)",
"人群基数": {
"人群基数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "32",
"年龄分组": "unspecified",
"发病数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "1.9",
"国家地区": "<sup>32</sup> Asia (South)",
"人群基数": {
"人群基数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "33",
"年龄分组": "unspecified",
"发病数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "3.3",
"国家地区": "<sup>33</sup> Asia (South-East)",
"人群基数": {
"人群基数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "34",
"年龄分组": "unspecified",
"发病数": "Asia Pacific (High Income): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "4.4",
"国家地区": "<sup>34</sup> Asia Pacific (High Income)",
"人群基数": {
"人群基数": "Asia Pacific (High Income): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "35",
"年龄分组": "unspecified",
"发病数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "8.8",
"国家地区": "<sup>35</sup> Australasia",
"人群基数": {
"人群基数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "36",
"年龄分组": "all ages",
"发病数": "11,186",
"发病率（per100,000）": "2.0",
"国家地区": "<sup>36</sup> Eastern Mediterranean",
"人群基数": {
"人群基数": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "37",
"年龄分组": "all ages",
"发病数": "144,836",
"发病率（per100,000）": "8.9",
"国家地区": "<sup>37</sup> Europe",
"人群基数": {
"人群基数": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "38",
"年龄分组": "unspecified",
"发病数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "8.6",
"国家地区": "<sup>38</sup> Europe (Central)",
"人群基数": {
"人群基数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "39",
"年龄分组": "unspecified",
"发病数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "10",
"国家地区": "<sup>39</sup> Europe (Eastern)",
"人群基数": {
"人群基数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "40",
"年龄分组": "unspecified",
"发病数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "9.2",
"国家地区": "<sup>40</sup> Europe (Western)",
"人群基数": {
"人群基数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "41",
"年龄分组": "unspecified",
"发病数": "Latin America (Andean): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "5",
"国家地区": "<sup>41</sup> Latin America (Andean)",
"人群基数": {
"人群基数": "Latin America (Andean): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "42",
"年龄分组": "unspecified",
"发病数": "Latin America (Central): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "5.7",
"国家地区": "<sup>42</sup> Latin America (Central)",
"人群基数": {
"人群基数": "Latin America (Central): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "43",
"年龄分组": "unspecified",
"发病数": "Latin America (Southern): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "11.6",
"国家地区": "<sup>43</sup> Latin America (Southern)",
"人群基数": {
"人群基数": "Latin America (Southern): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "44",
"年龄分组": "unspecified",
"发病数": "Latin America (Tropical): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "5",
"国家地区": "<sup>44</sup> Latin America (Tropical)",
"人群基数": {
"人群基数": "Latin America (Tropical): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "45",
"年龄分组": "unspecified",
"发病数": "North Africa/Middle East: 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "3.1",
"国家地区": "<sup>45</sup> North Africa/Middle East",
"人群基数": {
"人群基数": "North Africa/Middle East: 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "46",
"年龄分组": "unspecified",
"发病数": "North America (High-Income): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "12.2",
"国家地区": "<sup>46</sup> North America (High Income)",
"人群基数": {
"人群基数": "North America (High-Income): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "47",
"年龄分组": "unspecified",
"发病数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"发病率（per100,000）": "2.9",
"国家地区": "<sup>47</sup> Oceania",
"人群基数": {
"人群基数": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "48",
"年龄分组": "all ages",
"发病数": "22,769",
"发病率（per100,000）": "1.2",
"国家地区": "<sup>48</sup> Southeast Asia",
"人群基数": {
"人群基数": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "49",
"年龄分组": "all ages",
"发病数": "115,526",
"发病率（per100,000）": "4.0",
"国家地区": "<sup>49</sup> Western Pacific",
"人群基数": {
"人群基数": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "50",
"年龄分组": "all ages",
"发病数": "194,175",
"发病率（per100,000）": "9.71",
"国家地区": "<sup>50</sup> Developed Countries",
"人群基数": {
"人群基数": "Number of new cases and age-standardized incidence rate in 2013; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "51",
"年龄分组": "all ages",
"发病数": "100,326",
"发病率（per100,000）": "2.27",
"国家地区": "<sup>51</sup> Developing Countries",
"人群基数": {
"人群基数": "Number of new cases and age-standardized incidence rate in 2013; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "52",
"年龄分组": "all ages",
"发病数": "431,288",
"发病率（per100,000）": "4.6",
"国家地区": "<sup>52</sup> Worldwide",
"人群基数": {
"人群基数": "Number of kidney cancer cases in 2020 and age-standardized incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"是否有星号": "yes"
}
}
],
"incidence_notes_and_source": [
{
"序号": "1",
"注释文本": "Canada: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "2",
"注释文本": "U.S.: Estimated number of new kidney and renal pelvis cancer cases in 2022; census figure for all ages applied to incidence number to calculate rate (American Cancer Society; \"Cancer Facts and Figures 2022.\" Atlanta: American Cancer Society; 2022)",
"注释": "Estimated number of new kidney and renal pelvis cancer cases in 2022; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"American Cancer Society; \"Cancer Facts and Figures 2022.\" Atlanta: American Cancer Society; 2022"
]
},
{
"序号": "3",
"注释文本": "Brazil: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "4",
"注释文本": "Mexico: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "5",
"注释文本": "Denmark: 2019 annual incidence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate incidence number (Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610)",
"注释": "2019 annual incidence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610"
]
},
{
"序号": "6",
"注释文本": "Finland: 2019 annual incidence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate incidence number (Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610)",
"注释": " 2019 annual incidence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610"
]
},
{
"序号": "7",
"注释文本": "France: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "8",
"注释文本": "Germany: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "9",
"注释文本": "Italy: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "10",
"注释文本": "Norway: 2019 annual incidence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate incidence number (Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610)",
"注释": " 2019 annual incidence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610"
]
},
{
"序号": "11",
"注释文本": "Russia: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "12",
"注释文本": "Spain: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "13",
"注释文本": "Sweden: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "14",
"注释文本": "UK: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "15",
"注释文本": "China: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "16",
"注释文本": "India: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "17",
"注释文本": "Japan: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "18",
"注释文本": "Korea (South): 2022 age-standardized incidence rate of kidney cancer; no calculations made (Jung KW et al; \"Prediction of Cancer Incidence and Mortality in Korea, 2022.\" Cancer Research and Treatment; V.54; No.2; 4/2022; p345; DOI:10.4143/crt.2022.179)",
"注释": "2022 age-standardized incidence rate of kidney cancer; no calculations made",
"参考资料": [
"Jung KW et al; \"Prediction of Cancer Incidence and Mortality in Korea, 2022.\" Cancer Research and Treatment; V.54; No.2; 4/2022; p345; DOI:10.4143/crt.2022.179"
]
},
{
"序号": "19",
"注释文本": "Turkey: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "20",
"注释文本": "Kenya: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "21",
"注释文本": "Nigeria: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "22",
"注释文本": "South Africa: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "23",
"注释文本": "Australia: Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-adjusted incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
},
{
"序号": "24",
"注释文本": "Africa: 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "25",
"注释文本": "Africa (Central Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "Africa (Central Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "26",
"注释文本": "Africa (Eastern Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "Africa (Eastern Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "27",
"注释文本": "Africa (Southern Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "Africa (Southern Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "28",
"注释文本": "Africa (Western Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "Africa (Western Sub-Saharan): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "29",
"注释文本": "Americas: 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "30",
"注释文本": "Asia (Central): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "31",
"注释文本": "Asia (East): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "32",
"注释文本": "Asia (South): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "33",
"注释文本": "Asia (South-East): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "34",
"注释文本": "Asia Pacific (High Income): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "Asia Pacific (High Income): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "35",
"注释文本": "Australasia: 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "36",
"注释文本": "East Mediterranean: 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "37",
"注释文本": "Europe: 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "38",
"注释文本": "Europe (Central): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "39",
"注释文本": "Europe (Eastern): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "40",
"注释文本": "Europe (Western): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "41",
"注释文本": "Latin America (Andean): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "Latin America (Andean): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "42",
"注释文本": "Latin America (Central): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "Latin America (Central): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "43",
"注释文本": "Latin America (Southern): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "Latin America (Southern): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "44",
"注释文本": "Latin America (Tropical): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "Latin America (Tropical): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "45",
"注释文本": "North Africa/Middle East: 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "North Africa/Middle East: 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "46",
"注释文本": "North America (High-Income): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "North America (High-Income): 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "47",
"注释文本": "Oceania: 2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made (Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020)",
"注释": "2017 incidence rate of kidney cancer based on data from the Global Burden of Disease study in 195 countries and territories; no census figure available; no calculations made",
"参考资料": [
"Safiri S et al; \"The Burden of Kidney Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990–2017.\" Scientific Reports; V.10; 13862; 2020"
]
},
{
"序号": "48",
"注释文本": "Southeast Asia: 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "49",
"注释文本": "Western Pacific: 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of kidney cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "50",
"注释文本": "Developed Countries: Number of new cases and age-standardized incidence rate in 2013; both data points provided by original source; no calculations made (Dy GW et al; \"Global Burden of Urologic Cancers, 1990–2013.\" European Urology; V.71; No.3; 03/17; p437; DOI:10.1016/j.eururo.2016.10.008)",
"注释": "Number of new cases and age-standardized incidence rate in 2013; both data points provided by original source; no calculations made",
"参考资料": [
"Dy GW et al; \"Global Burden of Urologic Cancers, 1990–2013.\" European Urology; V.71; No.3; 03/17; p437; DOI:10.1016/j.eururo.2016.10.008"
]
},
{
"序号": "51",
"注释文本": "Developing Countries: Number of new cases and age-standardized incidence rate in 2013; both data points provided by original source; no calculations made (Dy GW et al; \"Global Burden of Urologic Cancers, 1990–2013.\" European Urology; V.71; No.3; 03/17; p437; DOI:10.1016/j.eururo.2016.10.008)",
"注释": "Number of new cases and age-standardized incidence rate in 2013; both data points provided by original source; no calculations made",
"参考资料": [
"Dy GW et al; \"Global Burden of Urologic Cancers, 1990–2013.\" European Urology; V.71; No.3; 03/17; p437; DOI:10.1016/j.eururo.2016.10.008"
]
},
{
"序号": "52",
"注释文本": "Worldwide: Number of kidney cancer cases in 2020 and age-standardized incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made (International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020)",
"注释": "Number of kidney cancer cases in 2020 and age-standardized incidence rate based on GLOBOCAN data; both data points provided by original source; no calculations made",
"参考资料": [
"International Agency for Cancer Research; \"Cancer Today.\" https://gco.iarc.fr/today/home; 2020"
]
}
]
},
{
"表名": "Cancer (All Sites); Cancer Complications",
"summary_content_incidence": [
{
"序号": "1",
"年龄分组": "all ages",
"发病数": "200,056",
"发病率（per100,000）": "519.4",
"国家地区": "<sup>1</sup> Canada",
"人群基数": {
"人群基数": "38,516,736",
"是否有星号": "yes"
}
},
{
"序号": "2",
"年龄分组": "all ages",
"发病数": "1,918,030",
"发病率（per100,000）": "564.7",
"国家地区": "<sup>2</sup> U.S.",
"人群基数": {
"人群基数": "339,665,118",
"是否有星号": "yes"
}
},
{
"序号": "3",
"年龄分组": "all ages",
"发病数": "95,808",
"发病率（per100,000）": "205.50",
"国家地区": "<sup>3</sup> Argentina",
"人群基数": {
"人群基数": "46,621,847",
"是否有星号": "yes"
}
},
{
"序号": "4",
"年龄分组": "all ages",
"发病数": "559,371",
"发病率（per100,000）": "255.8",
"国家地区": "<sup>4</sup> Brazil",
"人群基数": {
"人群基数": "218,689,757",
"是否有星号": "yes"
}
},
{
"序号": "5",
"年龄分组": "all ages",
"发病数": "190,667",
"发病率（per100,000）": "146.8",
"国家地区": "<sup>5</sup> Mexico",
"人群基数": {
"人群基数": "129,875,529",
"是否有星号": "yes"
}
},
{
"序号": "6",
"年龄分组": "all ages",
"发病数": "299,923",
"发病率（per100,000）": "2015 incidence rate of cancer; no census figure available; no calculations made",
"国家地区": "<sup>6</sup> England",
"人群基数": {
"人群基数": "2015 incidence rate of cancer; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "7",
"年龄分组": "all ages",
"发病数": "455,618",
"发病率（per100,000）": "664.9",
"国家地区": "<sup>7</sup> France",
"人群基数": {
"人群基数": "68,521,974",
"是否有星号": "yes"
}
},
{
"序号": "8",
"年龄分组": "all ages",
"发病数": "608,742",
"发病率（per100,000）": "722.8",
"国家地区": "<sup>8</sup> Germany",
"人群基数": {
"人群基数": "84,220,184",
"是否有星号": "yes"
}
},
{
"序号": "9",
"年龄分组": "all ages",
"发病数": "17,111",
"发病率（per100,000）": "163",
"国家地区": "<sup>9</sup> Greece",
"人群基数": {
"人群基数": "10,497,595",
"是否有星号": "yes"
}
},
{
"序号": "10",
"年龄分组": "all ages",
"发病数": "409,808",
"发病率（per100,000）": "671.6",
"国家地区": "<sup>10</sup> Italy",
"人群基数": {
"人群基数": "61,021,855",
"是否有星号": "yes"
}
},
{
"序号": "11",
"年龄分组": "all ages",
"发病数": "543,045",
"发病率（per100,000）": "383.2",
"国家地区": "<sup>11</sup> Russian Federation",
"人群基数": {
"人群基数": "141,698,923",
"是否有星号": "yes"
}
},
{
"序号": "12",
"年龄分组": "all ages",
"发病数": "270,363",
"发病率（per100,000）": "572.5",
"国家地区": "<sup>12</sup> Spain",
"人群基数": {
"人群基数": "47,222,613",
"是否有星号": "yes"
}
},
{
"序号": "13",
"年龄分组": "all ages",
"发病数": "60,853",
"发病率（per100,000）": "577.6",
"国家地区": "<sup>13</sup> Sweden",
"人群基数": {
"人群基数": "10,536,338",
"是否有星号": "yes"
}
},
{
"序号": "14",
"年龄分组": "all ages",
"发病数": "446,942",
"发病率（per100,000）": "655.9",
"国家地区": "<sup>14</sup> UK",
"人群基数": {
"人群基数": "68,138,484",
"是否有星号": "yes"
}
},
{
"序号": "15",
"年龄分组": "all ages",
"发病数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"发病率（per100,000）": "259",
"国家地区": "<sup>15</sup> Afghanistan",
"人群基数": {
"人群基数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"是否有星号": "yes"
}
},
{
"序号": "16",
"年龄分组": "all ages",
"发病数": "2,475,945",
"发病率（per100,000）": "343.3",
"国家地区": "<sup>16</sup> China (a)",
"人群基数": {
"人群基数": "721,230,798",
"是否有星号": "yes"
}
},
{
"序号": "16",
"年龄分组": "all ages",
"发病数": "2,092,809",
"发病率（per100,000）": "302.5",
"国家地区": "<sup>16</sup> China (b)",
"人群基数": {
"人群基数": "691,912,048",
"是否有星号": "yes"
}
},
{
"序号": "17",
"年龄分组": "all ages",
"发病数": "1,625,654",
"发病率（per100,000）": "225.4",
"国家地区": "<sup>17</sup> China (a)",
"人群基数": {
"人群基数": "721,230,798",
"是否有星号": "yes"
}
},
{
"序号": "17",
"年龄分组": "all ages",
"发病数": "1,302,178",
"发病率（per100,000）": "188.2",
"国家地区": "<sup>17</sup> China (b)",
"人群基数": {
"人群基数": "691,912,048",
"是否有星号": "yes"
}
},
{
"序号": "18",
"年龄分组": "all ages",
"发病数": "4,285,033",
"发病率（per100,000）": "303.2",
"国家地区": "<sup>18</sup> China",
"人群基数": {
"人群基数": "1,413,142,846",
"是否有星号": "yes"
}
},
{
"序号": "19",
"年龄分组": "all ages",
"发病数": "28,936",
"发病率（per100,000）": "397.0",
"国家地区": "<sup>19</sup> Hong Kong",
"人群基数": {
"人群基数": "7,288,167",
"是否有星号": "yes"
}
},
{
"序号": "20",
"年龄分组": "all ages",
"发病数": "689,823",
"发病率（per100,000）": "95.7",
"国家地区": "<sup>20</sup> India (a)",
"人群基数": {
"人群基数": "720,818,191",
"是否有星号": "yes"
}
},
{
"序号": "20",
"年龄分组": "all ages",
"发病数": "673,613",
"发病率（per100,000）": "99.3",
"国家地区": "<sup>20</sup> India (b)",
"人群基数": {
"人群基数": "678,361,394",
"是否有星号": "yes"
}
},
{
"序号": "21",
"年龄分组": "all ages",
"发病数": "1,157,294",
"发病率（per100,000）": "82.7",
"国家地区": "<sup>21</sup> India",
"人群基数": {
"人群基数": "1,399,179,585",
"是否有星号": "yes"
}
},
{
"序号": "22",
"年龄分组": "unspecified",
"发病数": "2016 age-standardized incidence rate of gynecological cancer in females; no age group specified; no calculations made",
"发病率（per100,000）": "12.3",
"国家地区": "<sup>22</sup> Iran (b)",
"人群基数": {
"人群基数": "2016 age-standardized incidence rate of gynecological cancer in females; no age group specified; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "23",
"年龄分组": "all ages",
"发病数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"发病率（per100,000）": "173",
"国家地区": "<sup>23</sup> Iran",
"人群基数": {
"人群基数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"是否有星号": "yes"
}
},
{
"序号": "24",
"年龄分组": "all ages",
"发病数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"发病率（per100,000）": "220",
"国家地区": "<sup>24</sup> Iraq",
"人群基数": {
"人群基数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"是否有星号": "yes"
}
},
{
"序号": "25",
"年龄分组": "all ages",
"发病数": "1,017,200",
"发病率（per100,000）": "822.2",
"国家地区": "<sup>25</sup> Japan",
"人群基数": {
"人群基数": "123,719,238",
"是否有星号": "yes"
}
},
{
"序号": "26",
"年龄分组": "all ages",
"发病数": "883,395",
"发病率（per100,000）": "714.0",
"国家地区": "<sup>26</sup> Japan",
"人群基数": {
"人群基数": "123,719,238",
"是否有星号": "yes"
}
},
{
"序号": "27",
"年龄分组": "all ages",
"发病数": "274,488",
"发病率（per100,000）": "528.2",
"国家地区": "<sup>27</sup> Korea (South)",
"人群基数": {
"人群基数": "51,966,948",
"是否有星号": "yes"
}
},
{
"序号": "28",
"年龄分组": "all ages",
"发病数": "143,792",
"发病率（per100,000）": "276.7",
"国家地区": "<sup>28</sup> Korea (South)",
"人群基数": {
"人群基数": "51,966,948",
"是否有星号": "yes"
}
},
{
"序号": "29",
"年龄分组": "all ages",
"发病数": "135,064",
"发病率（per100,000）": "116",
"国家地区": "<sup>29</sup> Philippines",
"人群基数": {
"人群基数": "116,434,200",
"是否有星号": "yes"
}
},
{
"序号": "30",
"年龄分组": "all ages",
"发病数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"发病率（per100,000）": "96",
"国家地区": "<sup>30</sup> Saudi Arabia",
"人群基数": {
"人群基数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"是否有星号": "yes"
}
},
{
"序号": "31",
"年龄分组": "all ages",
"发病数": "105,390",
"发病率（per100,000）": "151",
"国家地区": "<sup>31</sup> Thailand",
"人群基数": {
"人群基数": "69,794,997",
"是否有星号": "yes"
}
},
{
"序号": "32",
"年龄分组": "all ages",
"发病数": "210,537",
"发病率（per100,000）": "251.9",
"国家地区": "<sup>32</sup> Turkey",
"人群基数": {
"人群基数": "83,593,483",
"是否有星号": "yes"
}
},
{
"序号": "33",
"年龄分组": "all ages",
"发病数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"发病率（per100,000）": "207",
"国家地区": "<sup>33</sup> United Arab Emirates",
"人群基数": {
"人群基数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"是否有星号": "yes"
}
},
{
"序号": "34",
"年龄分组": "all ages",
"发病数": "152,270",
"发病率（per100,000）": "139",
"国家地区": "<sup>34</sup> Egypt",
"人群基数": {
"人群基数": "109,546,720",
"是否有星号": "yes"
}
},
{
"序号": "35",
"年龄分组": "all ages",
"发病数": "47,887",
"发病率（per100,000）": "83.9",
"国家地区": "<sup>35</sup> Kenya",
"人群基数": {
"人群基数": "57,052,004",
"是否有星号": "yes"
}
},
{
"序号": "36",
"年龄分组": "all ages",
"发病数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"发病率（per100,000）": "195",
"国家地区": "<sup>36</sup> Morocco",
"人群基数": {
"人群基数": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"是否有星号": "yes"
}
},
{
"序号": "37",
"年龄分组": "all ages",
"发病数": "115,950",
"发病率（per100,000）": "50.2",
"国家地区": "<sup>37</sup> Nigeria",
"人群基数": {
"人群基数": "230,842,743",
"是否有星号": "yes"
}
},
{
"序号": "38",
"年龄分组": "all ages",
"发病数": "107,467",
"发病率（per100,000）": "185.1",
"国家地区": "<sup>38</sup> South Africa",
"人群基数": {
"人群基数": "58,048,332",
"是否有星号": "yes"
}
},
{
"序号": "39",
"年龄分组": "all ages",
"发病数": "134,174",
"发病率（per100,000）": "507.1",
"国家地区": "<sup>39</sup> Australia",
"人群基数": {
"人群基数": "26,461,166",
"是否有星号": "yes"
}
},
{
"序号": "40",
"年龄分组": "all ages",
"发病数": "Australia/New Zealand: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "494.2",
"国家地区": "<sup>40</sup> Australia/New Zealand(a)",
"人群基数": {
"人群基数": "Australia/New Zealand: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "40",
"年龄分组": "all ages",
"发病数": "Australia/New Zealand: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "405.2",
"国家地区": "<sup>40</sup> Australia/New Zealand (b)",
"人群基数": {
"人群基数": "Australia/New Zealand: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "41",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"发病率（per100,000）": "132.1",
"国家地区": "<sup>41</sup> Africa",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "42",
"年龄分组": "all ages",
"发病数": "811,228",
"发病率（per100,000）": "127.0",
"国家地区": "<sup>42</sup> Africa",
"人群基数": {
"人群基数": "2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "43",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "112.9",
"国家地区": "<sup>43</sup> Africa (Eastern) (a)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "43",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "148.1",
"国家地区": "<sup>43</sup> Africa (Eastern) (b)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "44",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "109.5",
"国家地区": "<sup>44</sup> Africa (Middle) (a)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "44",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "115.8",
"国家地区": "<sup>44</sup> Africa (Middle) (b)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "45",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "145.7",
"国家地区": "<sup>45</sup> Africa (Northern) (a)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "45",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "140.1",
"国家地区": "<sup>45</sup> Africa (Northern) (b)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "46",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "232.7",
"国家地区": "<sup>46</sup> Africa (Southern) (a)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "46",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "189.0",
"国家地区": "<sup>46</sup> Africa (Southern) (b)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "47",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "100.6",
"国家地区": "<sup>47</sup> Africa (Western) (a)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "47",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "123.2",
"国家地区": "<sup>47</sup> Africa (Western) (b)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "48",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "140.7",
"国家地区": "<sup>48</sup> America (Central)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "49",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "141.1",
"国家地区": "<sup>49</sup> America (Central)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "50",
"年龄分组": "all ages",
"发病数": "3,791,517",
"发病率（per100,000）": "265.2",
"国家地区": "<sup>50</sup> Americas",
"人群基数": {
"人群基数": " 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "51",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"发病率（per100,000）": "169.1",
"国家地区": "<sup>51</sup> Asia",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "52",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "242.3",
"国家地区": "<sup>52</sup> Asia (Eastern)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "53",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "196.4",
"国家地区": "<sup>53</sup> Asia (Eastern)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "54",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "159.2",
"国家地区": "<sup>54</sup> Asia (South-East) (a)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "54",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "149.3",
"国家地区": "<sup>54</sup> Asia (South-East) (b)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "55",
"年龄分组": "all ages",
"发病数": "Asia (South and Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "103.2",
"国家地区": "<sup>55</sup> Asia (South and Central)",
"人群基数": {
"人群基数": "Asia (South and Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "56",
"年龄分组": "all ages",
"发病数": "Asia (South and Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "102.5",
"国家地区": "<sup>56</sup> Asia (South and Central)",
"人群基数": {
"人群基数": "Asia (South and Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "57",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "198.3",
"国家地区": "<sup>57</sup> Asia (Western)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "58",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "162.3",
"国家地区": "<sup>58</sup> Asia (Western)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "59",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "213.9",
"国家地区": "<sup>59</sup> Caribbean (a)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "59",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "174.6",
"国家地区": "<sup>59</sup> Caribbean (b)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "60",
"年龄分组": "all ages",
"发病数": "676,508",
"发病率（per100,000）": "125.8",
"国家地区": "<sup>60</sup> Eastern Mediterranean",
"人群基数": {
"人群基数": "Eastern Mediterranean: 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "61",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"发病率（per100,000）": "285.2",
"国家地区": "<sup>61</sup> Europe",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "62",
"年龄分组": "all ages",
"发病数": "4,573,972",
"发病率（per100,000）": "268.6",
"国家地区": "<sup>62</sup> Europe",
"人群基数": {
"人群基数": " 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "63",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "293.8",
"国家地区": "<sup>63</sup> Europe (Eastern)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "64",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "220.9",
"国家地区": "<sup>64</sup> Europe (Eastern)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "65",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "343.7",
"国家地区": "<sup>65</sup> Europe (Northern)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "66",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "296.5",
"国家地区": "<sup>66</sup> Europe (Northern)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "67",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "317.8",
"国家地区": "<sup>67</sup> Europe (Southern)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "68",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "249.9",
"国家地区": "<sup>68</sup> Europe (Southern)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "69",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "365.3",
"国家地区": "<sup>69</sup> Europe (Western)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "70",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "294.3",
"国家地区": "<sup>70</sup> Europe (Western)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "71",
"年龄分组": "all ages",
"发病数": "Latin America and Caribbean: 2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"发病率（per100,000）": "186.5",
"国家地区": "<sup>71</sup> Latin America and Caribbean",
"人群基数": {
"人群基数": "Latin America and Caribbean: 2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "72",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "192.6",
"国家地区": "<sup>72</sup> Melanesia",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "73",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "202.5",
"国家地区": "<sup>73</sup> Melanesia",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "74",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"发病率（per100,000）": "360.7",
"国家地区": "<sup>74</sup> North America",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "75",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "397.9",
"国家地区": "<sup>75</sup> North America (a)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "75",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "332.6",
"国家地区": "<sup>75</sup> North America (b)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "76",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"发病率（per100,000）": "404.6",
"国家地区": "<sup>76</sup> Oceania",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "77",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "217.1",
"国家地区": "<sup>77</sup> South America (a)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "77",
"年龄分组": "all ages",
"发病数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"发病率（per100,000）": "192.2",
"国家地区": "<sup>77</sup> South America (b)",
"人群基数": {
"人群基数": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"是否有星号": "yes"
}
},
{
"序号": "78",
"年龄分组": "all ages",
"发病数": "2,003,789",
"发病率（per100,000）": "103.4",
"国家地区": "<sup>78</sup> Southeast Asia",
"人群基数": {
"人群基数": " 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "79",
"年龄分组": "all ages",
"发病数": "6,218,238",
"发病率（per100,000）": "213.0",
"国家地区": "<sup>79</sup> Western Pacific",
"人群基数": {
"人群基数": " 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "80",
"年龄分组": "all ages",
"发病数": "Incidence rate in 2013; no census figure available; no calculations made",
"发病率（per100,000）": "327.9",
"国家地区": "<sup>80</sup> Developed Countries",
"人群基数": {
"人群基数": "Incidence rate in 2013; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "81",
"年龄分组": "all ages",
"发病数": "Incidence rate in 2013; no census figure available; no calculations made",
"发病率（per100,000）": "190.4",
"国家地区": "<sup>81</sup> Developing Countries",
"人群基数": {
"人群基数": "Incidence rate in 2013; no census figure available; no calculations made",
"是否有星号": "yes"
}
},
{
"序号": "82",
"年龄分组": "all ages",
"发病数": "16,038,315",
"发病率（per100,000）": "201.0",
"国家地区": "<sup>82</sup> Worldwide",
"人群基数": {
"人群基数": "7,979,261,010",
"是否有星号": "yes"
}
},
{
"序号": "83",
"年龄分组": "all ages",
"发病数": "8,895,909",
"发病率（per100,000）": "222.0",
"国家地区": "<sup>83</sup> Worldwide (a)",
"人群基数": {
"人群基数": "4,007,166,079",
"是否有星号": "yes"
}
},
{
"序号": "83",
"年龄分组": "all ages",
"发病数": "7,388,097",
"发病率（per100,000）": "186.0",
"国家地区": "<sup>83</sup> Worldwide (b)",
"人群基数": {
"人群基数": "3,972,094,931",
"是否有星号": "yes"
}
},
{
"序号": "84",
"年龄分组": "all ages",
"发病数": "18,078,957",
"发病率（per100,000）": "226.6",
"国家地区": "<sup>84</sup> Worldwide",
"人群基数": {
"人群基数": "7,979,261,010",
"是否有星号": "yes"
}
}
],
"incidence_notes_and_source": [
{
"序号": "1",
"注释文本": "Canada: 2020 projected age-standardized incidence rate of all cancers; census figure for all ages applied to rate to calculate incidence number (Brenner DR et al; \"Projected Estimates of Cancer in Canada in 2020.\" Canadian Medical Association Journal; V.192; No.9; 3/2/2020; pE199; DOI:10.1503/cmaj.191292)",
"注释": "2020 projected age-standardized incidence rate of all cancers; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Brenner DR et al; \"Projected Estimates of Cancer in Canada in 2020.\" Canadian Medical Association Journal; V.192; No.9; 3/2/2020; pE199; DOI:10.1503/cmaj.191292"
]
},
{
"序号": "2",
"注释文本": "U.S.: Estimated number of new cancer cases in 2022; census figure for all ages applied to incidence number to calculate rate (American Cancer Society; \"Cancer Facts and Figures 2022.\" Atlanta: American Cancer Society; 2022)",
"注释": "Estimated number of new cancer cases in 2022; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"American Cancer Society; \"Cancer Facts and Figures 2022.\" Atlanta: American Cancer Society; 2022"
]
},
{
"序号": "3",
"注释文本": "Argentina: 2012 incidence rate; census figure for all ages applied to rate to calculate incidence number (International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1)",
"注释": "2012 incidence rate; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1"
]
},
{
"序号": "4",
"注释文本": "Brazil: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "5",
"注释文本": "Mexico: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "6",
"注释文本": "England: 2015 incidence rate of cancer; no census figure available; no calculations made (\"Cancer Registration Statistics, England: First Release, 2015.\" Office for National Statistics; 2/22/17)",
"注释": "2015 incidence rate of cancer; no census figure available; no calculations made",
"参考资料": [
"\"Cancer Registration Statistics, England: First Release, 2015.\" Office for National Statistics; 2/22/17"
]
},
{
"序号": "7",
"注释文本": "France: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "8",
"注释文本": "Germany: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "9",
"注释文本": "Greece: 2012 incidence rate; census figure for all ages applied to rate to calculate incidence number (International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1)",
"注释": "2012 incidence rate; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1"
]
},
{
"序号": "10",
"注释文本": "Italy: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "11",
"注释文本": "Russian Federation: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "12",
"注释文本": "Spain: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "13",
"注释文本": "Sweden: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "14",
"注释文本": "UK: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "15",
"注释文本": "Afghanistan: Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number (GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9)",
"注释": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9"
]
},
{
"序号": "16",
"注释文本": "China: Estimated number of new cancer cases in males (a) and females (b) in 2020 based on data from a GLOBOCAN study; census figure for all ages applied to incidence number to calculate rate (Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474)",
"注释": "Estimated number of new cancer cases in males (a) and females (b) in 2020 based on data from a GLOBOCAN study; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474"
]
},
{
"序号": "17",
"注释文本": "China: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; census figure for all ages applied to rate to calculate incidence number (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "18",
"注释文本": "China: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "19",
"注释文本": "Hong Kong: Number of new cases in 2013; census figure for all ages applied to incidence number to calculate rate (Ngan RKC; \"Overview of 2013 HK Cancer Statistics.\" Hong Kong Cancer Registry, Hospital Authority; 12/30/15; p1)",
"注释": "Number of new cases in 2013; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ngan RKC; \"Overview of 2013 HK Cancer Statistics.\" Hong Kong Cancer Registry, Hospital Authority; 12/30/15; p1"
]
},
{
"序号": "20",
"注释文本": "India: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; census figure for all ages applied to rate to calculate incidence number (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "21",
"注释文本": "India: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "22",
"注释文本": "Iran: 2016 age-standardized incidence rate of gynecological cancer in females; no age group specified; no calculations made (Eftekharzadeh S et al; \"National and Subnational Trends of Incidence and Mortality of Female Genital Cancers in Iran; 1990-2016.\" Archives of Iranian Medicine; V.23; No.7; 7/1/2020; p434; DOI:10.34172/aim.2020.40)",
"注释": "2016 age-standardized incidence rate of gynecological cancer in females; no age group specified; no calculations made",
"参考资料": [
"Eftekharzadeh S et al; \"National and Subnational Trends of Incidence and Mortality of Female Genital Cancers in Iran; 1990-2016.\" Archives of Iranian Medicine; V.23; No.7; 7/1/2020; p434; DOI:10.34172/aim.2020.40"
]
},
{
"序号": "23",
"注释文本": "Iran: Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number (GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9)",
"注释": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9"
]
},
{
"序号": "24",
"注释文本": "Iraq: Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number (GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9)",
"注释": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9"
]
},
{
"序号": "25",
"注释文本": "Japan: Projected number of cancer cases in 2019 (males: 572,600; females: 444,600); census figure for all ages applied to incidence number to calculate rate (Foundation for Promotion of Cancer Research; \"Cancer Statistics in Japan – 2019.\" https://ganjoho.jp/data/reg_stat/statistics/brochure/2019/cancer_statistics_2019.pdf; 3/2020)",
"注释": "Projected number of cancer cases in 2019 (males: 572,600; females: 444,600); census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Foundation for Promotion of Cancer Research; \"Cancer Statistics in Japan – 2019.\" https://ganjoho.jp/data/reg_stat/statistics/brochure/2019/cancer_statistics_2019.pdf; 3/2020"
]
},
{
"序号": "26",
"注释文本": "Japan: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "27",
"注释文本": "Korea (South): Number of new cancer cases (all sites) in 2022; census figure for all ages applied to incidence number to calculate rate (Jung KW et al; \"Prediction of Cancer Incidence and Mortality in Korea, 2022.\" Cancer Research and Treatment; V.54; No.2; 4/2022; p345; DOI:10.4143/crt.2022.179)",
"注释": "Number of new cancer cases (all sites) in 2022; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Jung KW et al; \"Prediction of Cancer Incidence and Mortality in Korea, 2022.\" Cancer Research and Treatment; V.54; No.2; 4/2022; p345; DOI:10.4143/crt.2022.179"
]
},
{
"序号": "28",
"注释文本": "Korea (South): 2022 age-standardized incidence rate of cancer (all sites); census figure for all ages applied to rate to calculate incidence number (Jung KW et al; \"Prediction of Cancer Incidence and Mortality in Korea, 2022.\" Cancer Research and Treatment; V.54; No.2; 4/2022; p345; DOI:10.4143/crt.2022.179)",
"注释": "2022 age-standardized incidence rate of cancer (all sites); census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Jung KW et al; \"Prediction of Cancer Incidence and Mortality in Korea, 2022.\" Cancer Research and Treatment; V.54; No.2; 4/2022; p345; DOI:10.4143/crt.2022.179"
]
},
{
"序号": "29",
"注释文本": "Philippines: 2008 incidence rate; census figure for all ages applied to rate to calculate incidence number (Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1)",
"注释": "2008 incidence rate; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1"
]
},
{
"序号": "30",
"注释文本": "Saudi Arabia: Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number (GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9)",
"注释": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9"
]
},
{
"序号": "31",
"注释文本": "Thailand: 2008 incidence rate; census figure for all ages applied to rate to calculate incidence number (Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1)",
"注释": "2008 incidence rate; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1"
]
},
{
"序号": "32",
"注释文本": "Turkey: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "33",
"注释文本": "United Arab Emirates: Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number (GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9)",
"注释": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9"
]
},
{
"序号": "34",
"注释文本": "Egypt: 2015 incidence rate; census figure for all ages applied to rate to calculate incidence number (GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9)",
"注释": "2015 incidence rate; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9"
]
},
{
"序号": "35",
"注释文本": "Kenya: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "36",
"注释文本": "Morocco: Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number (GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9)",
"注释": "Age-standardized incidence rate in 2015; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"GBD 2015 Eastern Mediterranean Region Cancer Collaborators; \"Burden of Cancer in the Eastern Mediterranean Region, 2005–2015: Findings From the Global Burden of Disease 2015 Study.\" International Journal of Public Health; 8/3/2017; p1; DOI:10.1007/s00038-017-0999-9"
]
},
{
"序号": "37",
"注释文本": "Nigeria: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "38",
"注释文本": "South Africa: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "39",
"注释文本": "Australia: Estimated number of cancer cases diagnosed in 2017; census figure for all ages applied to incidence number to calculate rate (Australian Institute of Health and Welfare; \"Cancer in Australia: Actual Incidence Data From 1982 to 2013 and Mortality Data From 1982 to 2014 With Projections to 2017.\" Asia-Pacific Journal of Clinical Oncology; V.14; No.1; 2/18; p5; DOI:10.1111/ajco.12761)",
"注释": "Estimated number of cancer cases diagnosed in 2017; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Australian Institute of Health and Welfare; \"Cancer in Australia: Actual Incidence Data From 1982 to 2013 and Mortality Data From 1982 to 2014 With Projections to 2017.\" Asia-Pacific Journal of Clinical Oncology; V.14; No.1; 2/18; p5; DOI:10.1111/ajco.12761"
]
},
{
"序号": "40",
"注释文本": "Australia/New Zealand: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "Australia/New Zealand: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "41",
"注释文本": "Africa: 2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made (Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474)",
"注释": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"参考资料": [
"Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474"
]
},
{
"序号": "42",
"注释文本": "Africa: 2018 incidence rate and number of cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": "2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "43",
"注释文本": "Africa (Eastern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "44",
"注释文本": "Africa (Middle): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "45",
"注释文本": "Africa (Northern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "46",
"注释文本": "Africa (Southern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "47",
"注释文本": "Africa (Western): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "48",
"注释文本": "America (Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "49",
"注释文本": "America (Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "50",
"注释文本": "Americas: 2018 incidence rate and number of cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "51",
"注释文本": "Asia: 2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made (Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474)",
"注释": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"参考资料": [
"Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474"
]
},
{
"序号": "52",
"注释文本": "Asia (Eastern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "53",
"注释文本": "Asia (Eastern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "54",
"注释文本": "Asia (South-East): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "55",
"注释文本": "Asia (South and Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "Asia (South and Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "56",
"注释文本": "Asia (South and Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "Asia (South and Central): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "57",
"注释文本": "Asia (Western): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "58",
"注释文本": "Asia (Western): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "59",
"注释文本": "Caribbean: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "60",
"注释文本": "Eastern Mediterranean: 2018 incidence rate and number of cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": "Eastern Mediterranean: 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "61",
"注释文本": "Europe: 2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made (Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474)",
"注释": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"参考资料": [
"Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474"
]
},
{
"序号": "62",
"注释文本": "Europe: 2018 incidence rate and number of cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "63",
"注释文本": "Europe (Eastern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "64",
"注释文本": "Europe (Eastern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "65",
"注释文本": "Europe (Northern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "66",
"注释文本": "Europe (Northern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "67",
"注释文本": "Europe (Southern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "68",
"注释文本": "Europe (Southern): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "69",
"注释文本": "Europe (Western): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "70",
"注释文本": "Europe (Western): 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "71",
"注释文本": "Latin America and Caribbean: 2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made (Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474)",
"注释": "Latin America and Caribbean: 2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"参考资料": [
"Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474"
]
},
{
"序号": "72",
"注释文本": "Melanesia: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "73",
"注释文本": "Melanesia: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in females based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "74",
"注释文本": "North America: 2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made (Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474)",
"注释": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"参考资料": [
"Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474"
]
},
{
"序号": "75",
"注释文本": "North America: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "76",
"注释文本": "Oceania: 2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made (Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474)",
"注释": "2020 age-standardized incidence rate of all cancers based on data from the GLOBOCAN study; no census figure available; no calculations were made",
"参考资料": [
"Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474"
]
},
{
"序号": "77",
"注释文本": "South America: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; no census figures available; no calculations were made",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "78",
"注释文本": "Southeast Asia: 2018 incidence rate and number of cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "79",
"注释文本": "Western Pacific: 2018 incidence rate and number of cancer cases; no census figure available; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " 2018 incidence rate and number of cancer cases; no census figure available; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "80",
"注释文本": "Developed Countries: Incidence rate in 2013; no census figure available; no calculations made (Global Burden of Disease Cancer Collaboration; \"The Global Burden of Cancer 2013.\" JAMA Oncology; V.1; 7/1/15; p505; DOI:10.1001/jamaoncol.2015.0735)",
"注释": "Incidence rate in 2013; no census figure available; no calculations made",
"参考资料": [
"Global Burden of Disease Cancer Collaboration; \"The Global Burden of Cancer 2013.\" JAMA Oncology; V.1; 7/1/15; p505; DOI:10.1001/jamaoncol.2015.0735"
]
},
{
"序号": "81",
"注释文本": "Developing Countries: Incidence rate in 2013; no census figure available; no calculations made (Global Burden of Disease Cancer Collaboration; \"The Global Burden of Cancer 2013.\" JAMA Oncology; V.1; 7/1/15; p505; DOI:10.1001/jamaoncol.2015.0735)",
"注释": "Incidence rate in 2013; no census figure available; no calculations made",
"参考资料": [
"Global Burden of Disease Cancer Collaboration; \"The Global Burden of Cancer 2013.\" JAMA Oncology; V.1; 7/1/15; p505; DOI:10.1001/jamaoncol.2015.0735"
]
},
{
"序号": "82",
"注释文本": "Worldwide: 2020 age-standardized incidence rate of all cancers based on data from a GLOBOCAN study; census figure for all ages applied to rate to calculate incidence number (Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474)",
"注释": "2020 age-standardized incidence rate of all cancers based on data from a GLOBOCAN study; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Cao W et al; \"Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020.\" Chinese Medical Journal; V.134; No.7; 4/5/2021; p783; DOI:10.1097/CM9.0000000000001474"
]
},
{
"序号": "83",
"注释文本": "Worldwide: 2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; census figure for all ages applied to rate to calculate incidence number (Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660)",
"注释": "2020 age-standardized incidence rate of all cancers combined (including non-melanoma skin cancer) in males (a) and females (b) based on data from the International Agency for Research on Cancer and GLOBOCAN; census figure for all ages applied to rate to calculate incidence number",
"参考资料": [
"Sung H et al; \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\" CA: A Cancer Journal for Clinicians; V.71; No.3; 5/2021; p209; DOI:10.3322/caac.21660"
]
},
{
"序号": "84",
"注释文本": "Worldwide: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
}
]
}
],
"summary_table_other": [],
"summary_table_prevalence": [
{
"表名": "Kidney Cancer (Renal Cancer); Renal Pelvis Cancer",
"summary_content_prevalence": [
{
"序号": "1",
"年龄分组": "all ages",
"国家地区": "<sup>1</sup> Canada",
"人群基数": {
"人群基数": "38,516,736",
"是否有星号": "yes"
},
"患病率人数": "19,918",
"患病率": [
{
"患病率数据": "51.7",
"是否加粗": "no",
"患病率单位": "(per 100,000)"
}
]
},
{
"序号": "2",
"年龄分组": "all ages",
"国家地区": "<sup>2</sup> U.S.",
"人群基数": {
"人群基数": "339,665,118",
"是否有星号": "yes"
},
"患病数": "170,958",
"患病率": [
{
"数据": "50.3",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "3",
"年龄分组": "all ages",
"国家地区": "<sup>3</sup> U.S. (a)",
"人群基数": {
"人群基数": "167,444,610",
"是否有星号": "yes"
},
"患病数": "305,340",
"患病率": [
{
"数据": "182.4",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "3",
"年龄分组": "all ages",
"国家地区": "<sup>3</sup> U.S. (b)",
"人群基数": {
"人群基数": "172,220,508",
"是否有星号": "yes"
},
"患病数": "204,040",
"患病率": [
{
"数据": "118.5",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "4",
"年龄分组": "15+",
"国家地区": "<sup>4</sup> Argentina",
"人群基数": {
"人群基数": "35,660,621",
"是否有星号": "yes"
},
"患病数": "11,661",
"患病率": [
{
"数据": "32.70",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "5",
"年龄分组": "all ages",
"国家地区": "<sup>5</sup> Brazil",
"人群基数": {
"人群基数": "218,689,757",
"是否有星号": "yes"
},
"患病数": "25,625",
"患病率": [
{
"数据": "11.7",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "6",
"年龄分组": "all ages",
"国家地区": "<sup>6</sup> Mexico",
"人群基数": {
"人群基数": "129,875,529",
"是否有星号": "yes"
},
"患病数": "10,821",
"患病率": [
{
"数据": "8.3",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "7",
"年龄分组": "all ages",
"国家地区": "<sup>7</sup> Denmark",
"人群基数": {
"人群基数": "5,946,984",
"是否有星号": "yes"
},
"患病数": "5,876",
"患病率": [
{
"数据": "98.8",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "8",
"年龄分组": "all ages",
"国家地区": "<sup>8</sup> Finland",
"人群基数": {
"人群基数": "5,614,571",
"是否有星号": "yes"
},
"患病数": "8,164",
"患病率": [
{
"数据": "145.4",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "9",
"年龄分组": "all ages",
"国家地区": "<sup>9</sup> France",
"人群基数": {
"人群基数": "68,521,974",
"是否有星号": "yes"
},
"患病数": "43,192",
"患病率": [
{
"数据": "63.0",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "10",
"年龄分组": "all ages",
"国家地区": "<sup>10</sup> Germany",
"人群基数": {
"人群基数": "84,220,184",
"是否有星号": "yes"
},
"患病数": "46,084",
"患病率": [
{
"数据": "54.7",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "11",
"年龄分组": "15+",
"国家地区": "<sup>11</sup> Greece",
"人群基数": {
"人群基数": "9,025,490",
"是否有星号": "yes"
},
"患病数": "3,051",
"患病率": [
{
"数据": "33.80",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "12",
"年龄分组": "all ages",
"国家地区": "<sup>12</sup> Italy",
"人群基数": {
"人群基数": "61,021,855",
"是否有星号": "yes"
},
"患病数": "32,106",
"患病率": [
{
"数据": "52.6",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "13",
"年龄分组": "all ages",
"国家地区": "<sup>13</sup> Norway",
"人群基数": {
"人群基数": "5,597,924",
"是否有星号": "yes"
},
"患病数": "6,807",
"患病率": [
{
"数据": "121.6",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "14",
"年龄分组": "all ages",
"国家地区": "<sup>14</sup> Russian Federation",
"人群基数": {
"人群基数": "141,698,923",
"是否有星号": "yes"
},
"患病数": "59,403",
"患病率": [
{
"数据": "41.9",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "15",
"年龄分组": "all ages",
"国家地区": "<sup>15</sup> Spain",
"人群基数": {
"人群基数": "47,222,613",
"是否有星号": "yes"
},
"患病数": "21,584",
"患病率": [
{
"数据": "45.7",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "16",
"年龄分组": "all ages",
"国家地区": "<sup>16</sup> Sweden",
"人群基数": {
"人群基数": "10,536,338",
"是否有星号": "yes"
},
"患病数": "10,916",
"患病率": [
{
"数据": "103.6",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "17",
"年龄分组": "all ages",
"国家地区": "<sup>17</sup> Sweden",
"人群基数": {
"人群基数": "10,536,338",
"是否有星号": "yes"
},
"患病数": "3,656",
"患病率": [
{
"数据": "34.7",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "18",
"年龄分组": "all ages",
"国家地区": "<sup>18</sup> UK",
"人群基数": {
"人群基数": "68,138,484",
"是否有星号": "yes"
},
"患病数": "37,463",
"患病率": [
{
"数据": "55.0",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "19",
"年龄分组": "all ages",
"国家地区": "<sup>19</sup> Ukraine",
"人群基数": {
"人群基数": "43,306,477",
"是否有星号": "yes"
},
"患病数": "48,243",
"患病率": [
{
"数据": "111.4",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "20",
"年龄分组": "all ages",
"国家地区": "<sup>20</sup> China",
"人群基数": {
"人群基数": "1,413,142,846",
"是否有星号": "yes"
},
"患病数": "161,587",
"患病率": [
{
"数据": "11.4",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "21",
"年龄分组": "all ages",
"国家地区": "<sup>21</sup> India",
"人群基数": {
"人群基数": "1,399,179,585",
"是否有星号": "yes"
},
"患病数": "31,577",
"患病率": [
{
"数据": "2.3",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "22",
"年龄分组": "all ages",
"国家地区": "<sup>22</sup> Japan",
"人群基数": {
"人群基数": "123,719,238",
"是否有星号": "yes"
},
"患病数": "64,141",
"患病率": [
{
"数据": "51.8",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "23",
"年龄分组": "all ages",
"国家地区": "<sup>23</sup> Korea (South)",
"人群基数": {
"人群基数": "51,966,948",
"是否有星号": "yes"
},
"患病数": "50,674",
"患病率": [
{
"数据": "97.5",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "24",
"年龄分组": "all ages",
"国家地区": "<sup>24</sup> Korea (South)",
"人群基数": {
"人群基数": "51,966,948",
"是否有星号": "yes"
},
"患病数": "19,368",
"患病率": [
{
"数据": "37.3",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "25",
"年龄分组": "all ages",
"国家地区": "<sup>25</sup> Korea (South)",
"人群基数": {
"人群基数": "51,966,948",
"是否有星号": "yes"
},
"患病数": "22,606",
"患病率": [
{
"数据": "43.5",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "26",
"年龄分组": "15+",
"国家地区": "<sup>26</sup> Thailand",
"人群基数": {
"人群基数": "58,630,174",
"是否有星号": "yes"
},
"患病数": "2,228",
"患病率": [
{
"数据": "3.80",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "27",
"年龄分组": "all ages",
"国家地区": "<sup>27</sup> Turkey",
"人群基数": {
"人群基数": "83,593,483",
"是否有星号": "yes"
},
"患病数": "11,640",
"患病率": [
{
"数据": "13.9",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "28",
"年龄分组": "15+",
"国家地区": "<sup>28</sup> Egypt",
"人群基数": {
"人群基数": "71,894,269",
"是否有星号": "yes"
},
"患病数": "4,673",
"患病率": [
{
"数据": "6.50",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "29",
"年龄分组": "all ages",
"国家地区": "<sup>29</sup> Kenya",
"人群基数": {
"人群基数": "57,052,004",
"是否有星号": "yes"
},
"患病数": "1,142",
"患病率": [
{
"数据": "2.0",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "30",
"年龄分组": "all ages",
"国家地区": "<sup>30</sup> Nigeria",
"人群基数": {
"人群基数": "230,842,743",
"是否有星号": "yes"
},
"患病数": "2,862",
"患病率": [
{
"数据": "1.2",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "31",
"年龄分组": "all ages",
"国家地区": "<sup>31</sup> South Africa",
"人群基数": {
"人群基数": "58,048,332",
"是否有星号": "yes"
},
"患病数": "2,284",
"患病率": [
{
"数据": "3.9",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "32",
"年龄分组": "all ages",
"国家地区": "<sup>32</sup> Australia",
"人群基数": {
"人群基数": "26,461,166",
"是否有星号": "yes"
},
"患病数": "11,959",
"患病率": [
{
"数据": "45.2",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "33",
"年龄分组": "all ages",
"国家地区": "<sup>33</sup> Africa",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "20,983",
"患病率": [
{
"数据": "2.0",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "34",
"年龄分组": "all ages",
"国家地区": "<sup>34</sup> Americas",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "268,558",
"患病率": [
{
"数据": "26.4",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "35",
"年龄分组": "all ages",
"国家地区": "<sup>35</sup> Eastern Mediterranean",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "25,509",
"患病率": [
{
"数据": "3.7",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "36",
"年龄分组": "all ages",
"国家地区": "<sup>36</sup> Europe",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "382,191",
"患病率": [
{
"数据": "41.4",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "37",
"年龄分组": "all ages",
"国家地区": "<sup>37</sup> Southeast Asia",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "46,657",
"患病率": [
{
"数据": "2.3",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "38",
"年龄分组": "all ages",
"国家地区": "<sup>38</sup> Western Pacific",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "281,642",
"患病率": [
{
"数据": "14.6",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "39",
"年龄分组": "all ages",
"国家地区": "<sup>39</sup> Worldwide",
"人群基数": {
"人群基数": "7,979,261,010",
"是否有星号": "yes"
},
"患病数": "1,025,730",
"患病率": [
{
"数据": "12.9",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "40",
"年龄分组": "unspecified",
"国家地区": "<sup>40</sup> Worldwide",
"人群基数": {
"人群基数": "7,979,261,010",
"是否有星号": "yes"
},
"患病数": "1,289,000",
"患病率": [
{
"数据": "16.2",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
}
],
"prevalence_notes_and_source": [
{
"序号": "1",
"注释文本": "Canada: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "2",
"注释文本": "U.S.: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "3",
"注释文本": "U.S.: Estimated number of (a) male and (b) female kidney and renal pelvis cancer survivors as of 1 January 2016; census figure for all ages applied to prevalence number to calculate rate (American Cancer Society; \"Cancer Treatment and Survivorship Facts And Figures 2016-2017.\" Atlanta: American Cancer Society; 2016)",
"注释": "Estimated number of (a) male and (b) female kidney and renal pelvis cancer survivors as of 1 January 2016; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"American Cancer Society; \"Cancer Treatment and Survivorship Facts And Figures 2016-2017.\" Atlanta: American Cancer Society; 2016"
]
},
{
"序号": "4",
"注释文本": "Argentina: Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number (International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1)",
"注释": "Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number",
"参考资料": [
"International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1"
]
},
{
"序号": "5",
"注释文本": "Brazil: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "6",
"注释文本": "Mexico: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "7",
"注释文本": "Denmark: 2019 total prevalence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate prevalence number (Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610)",
"注释": " 2019 total prevalence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate prevalence number",
"参考资料": [
"Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610"
]
},
{
"序号": "8",
"注释文本": "Finland: 2019 total prevalence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate prevalence number (Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610)",
"注释": " 2019 total prevalence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate prevalence number",
"参考资料": [
"Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610"
]
},
{
"序号": "9",
"注释文本": "France: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "10",
"注释文本": "Germany: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "11",
"注释文本": "Greece: Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number (International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1)",
"注释": "Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number",
"参考资料": [
"International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1"
]
},
{
"序号": "12",
"注释文本": "Italy: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "13",
"注释文本": "Norway: 2019 total prevalence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate prevalence number (Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610)",
"注释": " 2019 total prevalence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate prevalence number",
"参考资料": [
"Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610"
]
},
{
"序号": "14",
"注释文本": "Russian Federation: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "15",
"注释文本": "Spain: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "16",
"注释文本": "Sweden: 2019 total prevalence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate prevalence number (Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610)",
"注释": " 2019 total prevalence rate of renal cancer using data from the NORDCAN database; census figure for all ages applied to rate to calculate prevalence number",
"参考资料": [
"Næraa SH et al; \"Burden of Renal Cancer in Nordic Countries.\" Scandinavian Journal of Urology; 6/7/2019; p1; DOI:10.1080/21681805.2019.1624610"
]
},
{
"序号": "17",
"注释文本": "Sweden: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "18",
"注释文本": "UK: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "19",
"注释文本": "Ukraine: Prevalence rate of kidney cancer; census figure for all ages applied to rate to calculate prevalence number (\"Bulletin of National Cancer Registry of Ukraine.\" National Cancer Institute of Ukraine; No.22; 2020)",
"注释": "Prevalence rate of kidney cancer; census figure for all ages applied to rate to calculate prevalence number",
"参考资料": [
"\"Bulletin of National Cancer Registry of Ukraine.\" National Cancer Institute of Ukraine; No.22; 2020"
]
},
{
"序号": "20",
"注释文本": "China: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "21",
"注释文本": "India: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "22",
"注释文本": "Japan: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "23",
"注释文本": "Korea (South): Number of prevalent kidney cancer cases in 2019 based on the Korea National Cancer Incidence Database; census figure for all ages applied to prevalence number to calculate rate (Kang MJ et al; \"Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019.\" Cancer Research and Treatment; V.54; No.2; 4/2022; p330; DOI:10.4143/crt.2022.128 )",
"注释": "Number of prevalent kidney cancer cases in 2019 based on the Korea National Cancer Incidence Database; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Kang MJ et al; \"Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019.\" Cancer Research and Treatment; V.54; No.2; 4/2022; p330; DOI:10.4143/crt.2022.128 "
]
},
{
"序号": "24",
"注释文本": "Korea (South): 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "25",
"注释文本": "Korea (South): Age-standardized prevalence rate of kidney cancer as of 1 January 2016; census figure for all ages applied to rate to calculate prevalence number (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Age-standardized prevalence rate of kidney cancer as of 1 January 2016; census figure for all ages applied to rate to calculate prevalence number",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "26",
"注释文本": "Thailand: Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number (Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1)",
"注释": "Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number",
"参考资料": [
"Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1"
]
},
{
"序号": "27",
"注释文本": "Turkey: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "28",
"注释文本": "Egypt: Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number (International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1)",
"注释": "Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number",
"参考资料": [
"International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1"
]
},
{
"序号": "29",
"注释文本": "Kenya: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "30",
"注释文本": "Nigeria: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "31",
"注释文本": "South Africa: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "32",
"注释文本": "Australia: 5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "33",
"注释文本": "Africa: Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "34",
"注释文本": "Americas: Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "35",
"注释文本": "East Mediterranean: Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "36",
"注释文本": "Europe: Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "37",
"注释文本": "Southeast Asia: Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "38",
"注释文本": "Western Pacific: Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of kidney cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "39",
"注释文本": "Worldwide: 5-year prevalence of kidney cancer in 2018 (data for 185 countries and territories); census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of kidney cancer in 2018 (data for 185 countries and territories); census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "40",
"注释文本": "Worldwide: 2016 prevalence of kidney cancer (data for 195 countries); census figure for all ages applied to prevalence number to calculate rate (GBD 2016 Disease and Injury Incidence and Prevalence Collaborators; \"Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016.\" The Lancet; V.390; 9/16/17; p1211; DOI:10.1016/S0140-6736(17)32154-2)",
"注释": "2016 prevalence of kidney cancer (data for 195 countries); census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators; \"Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016.\" The Lancet; V.390; 9/16/17; p1211; DOI:10.1016/S0140-6736(17)32154-2"
]
}
]
},
{
"表名": "Cancer (All Sites); Cancer Complications",
"summary_content_prevalence": [
{
"序号": "1",
"年龄分组": "all ages",
"国家地区": "<sup>1</sup> Canada",
"人群基数": {
"人群基数": "38,516,736",
"是否有星号": "yes"
},
"患病数": "852,727",
"患病率": [
{
"数据": "2,213.9",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "2",
"年龄分组": "all ages",
"国家地区": "<sup>2</sup> U.S.",
"人群基数": {
"人群基数": "339,665,118",
"是否有星号": "yes"
},
"患病数": "7,279,710",
"患病率": [
{
"数据": "2,143.2",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "3",
"年龄分组": "20+",
"国家地区": "<sup>3</sup> U.S.",
"人群基数": {
"人群基数": "256,693,231",
"是否有星号": "yes"
},
"患病数": "15,144,901",
"患病率": [
{
"数据": "5,900",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "4",
"年龄分组": "all ages",
"国家地区": "<sup>4</sup> U.S.",
"人群基数": {
"人群基数": "339,665,118",
"是否有星号": "yes"
},
"患病数": "15,500,000",
"患病率": [
{
"数据": "4,563.3",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "5",
"年龄分组": "15+",
"国家地区": "<sup>5</sup> Argentina",
"人群基数": {
"人群基数": "35,660,621",
"是否有星号": "yes"
},
"患病数": "315,169",
"患病率": [
{
"数据": "883.80",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "6",
"年龄分组": "all ages",
"国家地区": "<sup>6</sup> Brazil",
"人群基数": {
"人群基数": "218,689,757",
"是否有星号": "yes"
},
"患病数": "1,307,120",
"患病率": [
{
"数据": "597.7",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "7",
"年龄分组": "all ages",
"国家地区": "<sup>7</sup> Mexico",
"人群基数": {
"人群基数": "129,875,529",
"是否有星号": "yes"
},
"患病数": "471,497",
"患病率": [
{
"数据": "363.0",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "8",
"年龄分组": "all ages",
"国家地区": "<sup>8</sup> France",
"人群基数": {
"人群基数": "68,521,974",
"是否有星号": "yes"
},
"患病数": "1,390,878",
"患病率": [
{
"数据": "2,029.8",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "9",
"年龄分组": "all ages",
"国家地区": "<sup>9</sup> Germany",
"人群基数": {
"人群基数": "84,220,184",
"是否有星号": "yes"
},
"患病数": "1,943,860",
"患病率": [
{
"数据": "2,308.1",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "10",
"年龄分组": "15+",
"国家地区": "<sup>10</sup> Greece",
"人群基数": {
"人群基数": "9,025,490",
"是否有星号": "yes"
},
"患病数": "94,461",
"患病率": [
{
"数据": "1,046.60",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "11",
"年龄分组": "all ages",
"国家地区": "<sup>11</sup> Italy",
"人群基数": {
"人群基数": "61,021,855",
"是否有星号": "yes"
},
"患病数": "1,180,472",
"患病率": [
{
"数据": "1,934.5",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "12",
"年龄分组": "all ages",
"国家地区": "<sup>12</sup> Russian Federation",
"人群基数": {
"人群基数": "141,698,923",
"是否有星号": "yes"
},
"患病数": "1,364,500",
"患病率": [
{
"数据": "963.0",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "13",
"年龄分组": "all ages",
"国家地区": "<sup>13</sup> Spain",
"人群基数": {
"人群基数": "47,222,613",
"是否有星号": "yes"
},
"患病数": "772,853",
"患病率": [
{
"数据": "1,636.6",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "14",
"年龄分组": "all ages",
"国家地区": "<sup>14</sup> Sweden",
"人群基数": {
"人群基数": "10,536,338",
"是否有星号": "yes"
},
"患病数": "194,849",
"患病率": [
{
"数据": "1,849.3",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "15",
"年龄分组": "all ages",
"国家地区": "<sup>15</sup> UK",
"人群基数": {
"人群基数": "68,138,484",
"是否有星号": "yes"
},
"患病数": "1,368,257",
"患病率": [
{
"数据": "2,008.1",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "16",
"年龄分组": "all ages",
"国家地区": "<sup>16</sup> Ukraine",
"人群基数": {
"人群基数": "43,306,477",
"是否有星号": "yes"
},
"患病数": "1,269,486",
"患病率": [
{
"数据": "2931.4",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "17",
"年龄分组": "all ages",
"国家地区": "<sup>17</sup> China",
"人群基数": {
"人群基数": "1,413,142,846",
"是否有星号": "yes"
},
"患病数": "7,827,961",
"患病率": [
{
"数据": "553.9",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "18",
"年龄分组": "all ages",
"国家地区": "<sup>18</sup> India",
"人群基数": {
"人群基数": "1,399,179,585",
"是否有星号": "yes"
},
"患病数": "2,258,208",
"患病率": [
{
"数据": "161.4",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "19",
"年龄分组": "all ages",
"国家地区": "<sup>19</sup> Japan",
"人群基数": {
"人群基数": "123,719,238",
"是否有星号": "yes"
},
"患病数": "2,127,559",
"患病率": [
{
"数据": "1,719.7",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "20",
"年龄分组": "all ages",
"国家地区": "<sup>20</sup> Korea (South)",
"人群基数": {
"人群基数": "51,966,948",
"是否有星号": "yes"
},
"患病数": "748,954",
"患病率": [
{
"数据": "1,441.2",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "21",
"年龄分组": "all ages",
"国家地区": "<sup>21</sup> Korea (South)",
"人群基数": {
"人群基数": "51,966,948",
"是否有星号": "yes"
},
"患病数": "1,016,941",
"患病率": [
{
"数据": "1,956.9",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "22",
"年龄分组": "15+",
"国家地区": "<sup>22</sup> Philippines",
"人群基数": {
"人群基数": "80,934,527",
"是否有星号": "yes"
},
"患病数": "216,095",
"患病率": [
{
"数据": "267",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "23",
"年龄分组": "15+",
"国家地区": "<sup>23</sup> Thailand",
"人群基数": {
"人群基数": "58,630,174",
"是否有星号": "yes"
},
"患病数": "263,836",
"患病率": [
{
"数据": "450",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "24",
"年龄分组": "all ages",
"国家地区": "<sup>24</sup> Turkey",
"人群基数": {
"人群基数": "83,593,483",
"是否有星号": "yes"
},
"患病数": "470,851",
"患病率": [
{
"数据": "563.3",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "25",
"年龄分组": "all ages",
"国家地区": "<sup>25</sup> Egypt",
"人群基数": {
"人群基数": "109,546,720",
"是否有星号": "yes"
},
"患病数": "257,288",
"患病率": [
{
"数据": "234.9",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "26",
"年龄分组": "all ages",
"国家地区": "<sup>26</sup> Kenya",
"人群基数": {
"人群基数": "57,052,004",
"是否有星号": "yes"
},
"患病数": "86,592",
"患病率": [
{
"数据": "151.8",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "27",
"年龄分组": "all ages",
"国家地区": "<sup>27</sup> Nigeria",
"人群基数": {
"人群基数": "230,842,743",
"是否有星号": "yes"
},
"患病数": "211,052",
"患病率": [
{
"数据": "91.4",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "28",
"年龄分组": "all ages",
"国家地区": "<sup>28</sup> South Africa",
"人群基数": {
"人群基数": "58,048,332",
"是否有星号": "yes"
},
"患病数": "223,102",
"患病率": [
{
"数据": "384.3",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "29",
"年龄分组": "all ages",
"国家地区": "<sup>29</sup> Australia",
"人群基数": {
"人群基数": "26,461,166",
"是否有星号": "yes"
},
"患病数": "755,062",
"患病率": [
{
"数据": "2,853.5",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "30",
"年龄分组": "all ages",
"国家地区": "<sup>30</sup> Africa",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "1,450,836",
"患病率": [
{
"数据": "135.0",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "31",
"年龄分组": "all ages",
"国家地区": "<sup>31</sup> Americas",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "11,468,905",
"患病率": [
{
"数据": "1,129.0",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "32",
"年龄分组": "all ages",
"国家地区": "<sup>32</sup> Eastern Mediterranean",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "1,365,619",
"患病率": [
{
"数据": "196.6",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "33",
"年龄分组": "all ages",
"国家地区": "<sup>33</sup> Europe",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "12,907,315",
"患病率": [
{
"数据": "1,398.7",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "34",
"年龄分组": "all ages",
"国家地区": "<sup>34</sup> Southeast Asia",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "3,899,908",
"患病率": [
{
"数据": "196.1",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "35",
"年龄分组": "all ages",
"国家地区": "<sup>35</sup> Western Pacific",
"人群基数": {
"人群基数": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"是否有星号": "yes"
},
"患病数": "12,741,086",
"患病率": [
{
"数据": "658.8",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "36",
"年龄分组": "all ages",
"国家地区": "<sup>36</sup> Worldwide",
"人群基数": {
"人群基数": "7,979,261,010",
"是否有星号": "yes"
},
"患病数": "17,554,374",
"患病率": [
{
"数据": "220",
"是否加粗": "yes",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "37",
"年龄分组": "all ages",
"国家地区": "<sup>37</sup> Worldwide",
"人群基数": {
"人群基数": "7,979,261,010",
"是否有星号": "yes"
},
"患病数": "43,841,302",
"患病率": [
{
"数据": "549.4",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
},
{
"序号": "38",
"年龄分组": "all ages",
"国家地区": "<sup>38</sup> Worldwide",
"人群基数": {
"人群基数": "7,979,261,010",
"是否有星号": "yes"
},
"患病数": "42,986,000",
"患病率": [
{
"数据": "538.7",
"是否加粗": "no",
"其他占比单位": "(per 100,000)"
}
]
}
],
"患病情况参考资料和注释": [
{
"序号": "1",
"注释文本": "Canada: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "2",
"注释文本": "U.S.: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "3",
"注释文本": "U.S.: 2014-2015 age-adjusted respondent-reported prevalence rate of cancer in adults aged 20 or older; census figure for ages 20 or older applied to rate to calculate prevalence number (National Center for Health Statistics; \"Health, United States, 2016: With Chartbook on Long-Term Trends in Health.\" Library of Congress Catalog Number 76–641496; 2017)",
"注释": "2014-2015 age-adjusted respondent-reported prevalence rate of cancer in adults aged 20 or older; census figure for ages 20 or older applied to rate to calculate prevalence number",
"参考资料": [
"National Center for Health Statistics; \"Health, United States, 2016: With Chartbook on Long-Term Trends in Health.\" Library of Congress Catalog Number 76–641496; 2017"
]
},
{
"序号": "4",
"注释文本": "U.S.: Estimated number of cancer survivors in 2016; census figure for all ages applied to prevalence number to calculate rate (Bluethmann SM et al; \"Anticipating the \"Silver Tsunami\": Prevalence Trajectories and Comorbidity Burden Among Older Cancer Survivors in the United States.\" Cancer Epidemiology, Biomarkers And Prevention; V.25; No.7; 7/16; p1029; DOI:10.1158/1055-9965.EPI-16-0133)",
"注释": "Estimated number of cancer survivors in 2016; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Bluethmann SM et al; \"Anticipating the \"Silver Tsunami\": Prevalence Trajectories and Comorbidity Burden Among Older Cancer Survivors in the United States.\" Cancer Epidemiology, Biomarkers And Prevention; V.25; No.7; 7/16; p1029; DOI:10.1158/1055-9965.EPI-16-0133"
]
},
{
"序号": "5",
"注释文本": "Argentina: Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number (International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1)",
"注释": "Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number",
"参考资料": [
"International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1"
]
},
{
"序号": "6",
"注释文本": "Brazil: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "7",
"注释文本": "Mexico: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "8",
"注释文本": "France: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "9",
"注释文本": "Germany: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "10",
"注释文本": "Greece: Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number (International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1)",
"注释": "Estimated 5-year prevalence rate in adults aged 15 or older in 2012; census figure for ages 15 or older applied to rate to calculate prevalence number",
"参考资料": [
"International Agency for Research on Cancer; \"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.\" http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 3/14; p1"
]
},
{
"序号": "11",
"注释文本": "Italy: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "12",
"注释文本": "Russian Federation: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "13",
"注释文本": "Spain: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "14",
"注释文本": "Sweden: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "15",
"注释文本": "UK: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "16",
"注释文本": "Ukraine: Prevalence rate of cancer; census figure for all ages applied to rate to calculate prevalence number (\"Bulletin of National Cancer Registry of Ukraine.\" National Cancer Institute of Ukraine; No.22; 2020)",
"注释": "Prevalence rate of cancer; census figure for all ages applied to rate to calculate prevalence number",
"参考资料": [
"\"Bulletin of National Cancer Registry of Ukraine.\" National Cancer Institute of Ukraine; No.22; 2020"
]
},
{
"序号": "17",
"注释文本": "China: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "18",
"注释文本": "India: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "19",
"注释文本": "Japan: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "20",
"注释文本": "Korea (South): 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "21",
"注释文本": "Korea (South): Age-adjusted prevalence rate of cancer (all sites) as of 1 January 2016 ( adjusted using the Segi’s world standard population) ; census figure for all ages applied to rate to calculate prevalence number (Jung K-W et al; \"Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence 2015.\" Cancer Research and Treatment; V.50; No.2; 2018; p303; DOI:10.4143/crt.2018.143)",
"注释": "Age-adjusted prevalence rate of cancer (all sites) as of 1 January 2016 ( adjusted using the Segi’s world standard population) ; census figure for all ages applied to rate to calculate prevalence number",
"参考资料": [
"Jung K-W et al; \"Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence 2015.\" Cancer Research and Treatment; V.50; No.2; 2018; p303; DOI:10.4143/crt.2018.143"
]
},
{
"序号": "22",
"注释文本": "Philippines: Estimated 5-year prevalence rate in adults aged 15 or older in 2008; census figure for ages 15 or older applied to rate to calculate prevalence number (Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1)",
"注释": "Estimated 5-year prevalence rate in adults aged 15 or older in 2008; census figure for ages 15 or older applied to rate to calculate prevalence number",
"参考资料": [
"Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1"
]
},
{
"序号": "23",
"注释文本": "Thailand: Estimated 5-year prevalence rate in adults aged 15 or older in 2008; census figure for ages 15 or older applied to rate to calculate prevalence number (Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1)",
"注释": "Estimated 5-year prevalence rate in adults aged 15 or older in 2008; census figure for ages 15 or older applied to rate to calculate prevalence number",
"参考资料": [
"Ferlay J et al; \"GLOBOCAN 2008: Estimated Incidence, and Mortality and Prevalence Worldwide in 2008.\" IARC CancerBase No. 10; Lyon, France: International Agency for Research on Cancer; 2010; p1"
]
},
{
"序号": "24",
"注释文本": "Turkey: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "25",
"注释文本": "Egypt: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "26",
"注释文本": "Kenya: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "27",
"注释文本": "Nigeria: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "28",
"注释文本": "South Africa: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "29",
"注释文本": "Australia: 5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "5-year prevalence of cancer in 2018; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "30",
"注释文本": "Africa: Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "31",
"注释文本": "Americas: Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "32",
"注释文本": "East Mediterranean: Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "33",
"注释文本": "Europe: Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "34",
"注释文本": "Southeast Asia: Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "35",
"注释文本": "Western Pacific: Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made (International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018)",
"注释": " Estimated 5-year prevalence rate and number of cancer cases in 2018; no calculations made",
"参考资料": [
"International Association of Cancer Registries; \"Cancer Today: Data Visualization Tools for Exploring the Global Cancer Burden in 2018.\" http://gco.iarc.fr/today/home; 2018"
]
},
{
"序号": "36",
"注释文本": "Worldwide: 2019 age-standardized prevalence rate of neoplasms based on data from the Global Burden of Diseases, Injuries, and Risk Factors Study; census figure for all ages applied to rate to calculate prevalence number (Cieza A et al; \"Global Estimates of the Need for Rehabilitation Based on the Global Burden of Disease Study 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.\" Lancet; V.396; No.10267; 12/19/2021; p2006; DOI:10.1016/S0140-6736(20)32340-0)",
"注释": "2019 age-standardized prevalence rate of neoplasms based on data from the Global Burden of Diseases, Injuries, and Risk Factors Study; census figure for all ages applied to rate to calculate prevalence number",
"参考资料": [
"Cieza A et al; \"Global Estimates of the Need for Rehabilitation Based on the Global Burden of Disease Study 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.\" Lancet; V.396; No.10267; 12/19/2021; p2006; DOI:10.1016/S0140-6736(20)32340-0"
]
},
{
"序号": "37",
"注释文本": "Worldwide: Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate (Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18)",
"注释": "Number of new cancer cases in 2018; census figure for all ages applied to incidence number to calculate rate",
"参考资料": [
"Ferlay J et al; \"Global Cancer Observatory: Cancer Today.\" International Agency for Research on Cancer; https://gco.iarc.fr/today; Accessed 10/9/18"
]
},
{
"序号": "38",
"注释文本": "Worldwide: 2016 prevalence of all cancers; census figure for all ages applied to prevalence number to calculate rate (GBD 2016 Disease and Injury Incidence and Prevalence Collaborators; \"Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016.\" The Lancet; V.390; 9/16/17; p1211; DOI:10.1016/S0140-6736(17)32154-2)",
"注释": "2016 prevalence of all cancers; census figure for all ages applied to prevalence number to calculate rate",
"参考资料": [
"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators; \"Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016.\" The Lancet; V.390; 9/16/17; p1211; DOI:10.1016/S0140-6736(17)32154-2"
]
}
]
}
]
}
川公网安备51010702043165
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息